The QualityStocks Daily Thursday, December 21st, 2023

Today's Top 3 Investment Newsletters

MarketClub Analysis(LTRY) $3.6700 +180.17%

Green Car Stocks(MULN) $14.2500 +78.13%

QualityStocks(GROM) $1.3100 +56.60%

The QualityStocks Daily Stock List

Grom Social Enterprises (GROM)

Broad Street, QualityStocks, MarketClub Analysis, InvestorPlace, AwesomeStocks, The Wealth Report, The Stock Dork, Money Wealth Matters, BUYINS.NET, StocksEarning, StockEarnings and Small Caps reported earlier on Grom Social Enterprises (GROM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Grom Social Enterprises Inc. (NASDAQ: GROM) is a media, entertainment and technology firm that is focused on the provision of online web communities.

The firm has its headquarters in Boca Raton, Florida and was incorporated in 2009, on October 6th by Zach Marks. It serves consumers around the globe.

The company is focused on providing web filtering technology, family-friendly programming, and a safe and secure social media for children aged 13 and below.

The enterprise operates through the following subsidiaries: Grom Nutritional Services Inc., Grom Education Services Inc., Grom Social Enterprises, TD Holdings Ltd and Grom Social Inc. Grom Education Services Inc. operates its web filtering services, which are offered to government agencies and schools while Grom Nutritional Services Inc. markets and distributes nutritional supplements to children. TD Holdings operates through the Top Draw Animation Inc. and Top Draw Animation Hong Kong Ltd subsidiaries. These two subsidiaries are both engaged in the production of television series and animated films, with Top Draw Inc. producing award-winning animation content for some of the biggest global media firms in the world. In addition to this, the company also operates through Curiosity Ink Media, a cross-platform media and entertainment firm that serves families and children with original ground-breaking content.

The company recently appointed a new CEO for Curiosity Ink Media with more than two decades experience in the marketing industry to its ranks. This move will help improve the profile the subsidiary to investors which may encourage more investments into the firm as well as bring in additional revenue through the production of original content.

Grom Social Enterprises (GROM), closed Thursday's trading session at $1.31, up 56.6049%, on 5,554,402 volume with 00 trades. The average volume for the last 3 months is 2.123M and the stock's 52-week low/high is $0.80 /$75.40 .

Hookipa Pharma (HOOK)

StockMarketWatch, MarketBeat, The Street, QualityStocks, Trades Of The Day, CRWEFinance, CRWEWallStreet, DrStockPick, InvestorPlace, InvestorsUnderground, PennyOmega, PennyToBuck, BestOtc, StockHotTips, Wall Street Greek, StreetInsider, The Stock Dork, Timothy Sykes, TradersPro, Trading Markets and SpeculatingStocks reported earlier on Hookipa Pharma (HOOK), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Hookipa Pharma Inc. (NASDAQ: HOOK) is a biopharmaceutical firm which is engaged in the development of immunotherapeutics that target infectious ailments and cancer.

The firm has its headquarters in New York and was incorporated in 2011 by Daniel Pinschewer, Katherine Cohen, Lukas Flatz, Andreas Bergthaler and Rolf Zinkernagel. It operates as part of the pharmaceutical and medicine manufacturing industry, under the healthcare sector. The firm has two companies in its corporate family and serves consumers in Austria and the United States.

The clinical-stage company develops therapies based off of its arenavirus platform, which reprograms the immune system. It is party to a collaboration agreement with Gilead Sciences Inc., which entails the development of infectious disease candidates that support functional cures for chronic HIV and HBV infections.

The enterprise’s product pipeline is comprised of HB-202 and HB-201, its lead oncology product candidates, which are undergoing phase II clinical trials evaluating their effectiveness in treating HPV 16-positive cancers. It also develops HB-101, which is undergoing a double-blinded randomized phase 2 trial in patients who are waiting for kidney transplants from cytomegalovirus-positive donors. The enterprise utilizes off-the-shelf technologies like TheraT and VaxWave to elicit a response of antigen-specific killer T antibodies and cells, directly within a patient.

The company is focused on advancing its arenaviral platform technology, which may be useful in the development of cures for Hepatitis B and HIV. The development of these cures will not only benefit patients with these indications but also bring in significant revenue into the company, which will positively influence its growth and investments.

Hookipa Pharma (HOOK), closed Thursday's trading session at $0.8625, up 52.6549%, on 104,750,214 volume with 00 trades. The average volume for the last 3 months is 44,376 and the stock's 52-week low/high is $0.41 /$2.05 .

Tearlach Resources (TELHF)

We reported earlier on Tearlach Resources (TELHF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Tearlach Resources Ltd (OTCQB: TELHF) (CVE: TEA) (FRA: V44) is a company focused on acquiring and exploring for lithium projects.

The firm has its headquarters in Vancouver, Canada and was incorporated in 1986, on October 30th. It operates as part of the other industrial metals and mining industry, under the basic materials sector. The firm primarily serves consumers in the United States and Canada.

The enterprise holds 100% interest in the Pakwan Extension Claim block property, which comprises of 23 cell claims located in Ontario. It has an option to acquire 100% interest in the Ferland Project comprising 6 mining claims; Savant East Project made up of 6 mining claims; Harth Lithium Property which includes 6 claims that cover an area of 2,350 hectares; Wesley Lithium Project comprising 7 mining claims that cover an area of 3,250 hectares; Shelby Properties, which is made up of 6 claim groups covering an area of 9,701 hectares located in Ontario, as well as Margot Lithium Project comprising 102 claims covering an area of 2,706 hectares. In addition to this, the enterprise holds interest in the Rose North Lithium and Fliszar Lithium properties, which consists of 116 claims; and Muscovite Lithium Property, which is made up of 84 claims located in Quebec. Further, it also has an option to acquire 70% in the Gabriel Lithium Project in Nevada.

The company is focused on further defining and potentially developing the lithium resources across its portfolio, which may encourage additional investments into the company while also creating ways to generate value for its shareholders.

Tearlach Resources (TELHF), closed Thursday's trading session at $0.05, up 1.7915%, on 22,632 volume with 00 trades. The average volume for the last 3 months is 1,337 and the stock's 52-week low/high is $0.0374 /$2.65 .

MacDonald Mines Exploration (MCDMF)

We reported earlier on MacDonald Mines Exploration (MCDMF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

MacDonald Mines Exploration Ltd (OTC: MCDMF) (CVE: BMK) (FRA: 3M7) is a mineral exploration firm focused on acquiring, exploring for and developing mineral properties.

The firm has its headquarters in Toronto, Canada and was incorporated in 1936, on December 23rd. Prior to its name change, it was called MacDonald Mines Ltd. It operates as part of the gold industry, under the basic materials sector. The firm mainly serves consumers in Canada.

The enterprise explores for gold, copper, silver, nickel, and cobalt deposits. It is primarily focused on locating an economic deposit within its 100%-owned Scadding-Powerline-Jovan (SPJ) Project in Northeastern Ontario, located 20km east of the prolific Sudbury Mining Camp. The SPJ property comprises of the Powerline, Scadding, Jovan, Loney, Blueberry, and Golden Copper properties located east of Sudbury in Northern Ontario. The SPJ Project is located along the prospective McLaren Lake Fault Zone at the Alwyn Copper-Gold trend and the Glade Gold trend. It is targeting a system of interconnected precious and critical metals mineralization zones on an underexplored land package, which hosts the past producing Scadding Gold Mine and multiple known critical and precious metals prospects and showings. It also covers a Metasomatic Iron and Alkali-Calcic (MIAC) mineral system that formed polymetallic Cu-Au and Au-Co, Au, Silver, and REE exploration targets.

The company remains focused on advancing its exploration efforts at Alwyn, which are directed towards expanding Cu-Au mineralization, which has a confirmed strike length of approximately 400 meters. The success of its efforts will greatly influence investments and revenues into the company as well as its overall growth.

MacDonald Mines Exploration (MCDMF), closed Thursday's trading session at $0.0367, up 0%, on volume with 00 trades. The average volume for the last 3 months is 28,206 and the stock's 52-week low/high is $0.024 /$0.0751 .

Scandium International Mining (SCYYF)

We reported earlier on Scandium International Mining (SCYYF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Scandium International Mining Corp. (OTC: SCYYF) (TSE: SCY) (FRA: 0E6) is an exploration stage firm focused on exploring for, evaluating and developing specialty metals assets.

The firm has its headquarters in Reno, Nevada and was incorporated in 2006, on July 17th. Prior to its name change in November 2014, the firm was known as EMC Metals Corp. It operates as part of the other industrial metals and mining industry, under the basic materials sector. The firm serves consumers around the globe.

The enterprise’s advanced project is the Nyngan Scandium Project, located in New South Wales, Australia, on which it holds a mine lease grant, a development consent, and 100% of the mineral rights. The Nyngan Scandium Project site is located approximately 450km northwest of Sydney, New South Wales, Australia and approximately 20km due west from the town of Nyngan. It has a 100% interest in an exploration license which covers roughly 34.7km2 in NSW, Australia referred to as the Honeybugle Scandium Property. The property is comprised of 4 distinct magnetic anomalies: Woodlong, Seaford, Mallee Valley, and Yarran Park. Its Kiviniemi Scandium Property is located in the municipality of Rautalampi, Eastern Finland Province, approximately 350km northeast of Helsinki, by road. It also owns the Phoenix Critical Metals Recovery Project (CMR).

The company’s Nyngan Scandium project is positioned to become the world’s first scandium-only mining project. Scandium is a high-value metal with a growing market demand, which may mean significant increases in revenue for the company as well as value creation for its shareholders.

Scandium International Mining (SCYYF), closed Thursday's trading session at $0.0221, up 0%, on 4,900 volume with 00 trades. The average volume for the last 3 months is 8,807 and the stock's 52-week low/high is $0.0101 /$0.081 .

Nine Dragons Paper (NDGPF)

MarketBeat reported earlier on Nine Dragons Paper (NDGPF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Nine Dragons Paper Holdings Limited (OTC: NDGPF) (OTC: NDGPY) (HKG: 2689) (FRA: N3Y) is a paper products manufacturer that is focused on producing and selling packaging paper, recycled printing and writing paper, and specialty paper and pulp products.

The firm has its headquarters in Dongguan, China and was incorporated in 1995. It operates as part of the paper and paper products industry, under the basic materials sector. The firm mainly serves consumers in the People’s Republic of China, where it has established production bases in Dongguan, Hubei, Taicang, Chongqing, Leshan, Tianjin, Quanzhou, Shenyang, and Hebei. It has overseas markets including Malaysia, Vietnam, and the United States.

The company operates as a subsidiary of Best Result Holdings Limited. Its offerings include linerboard products, like white top, kraft, test, and coated linerboards; corrugated sheet products; corrugating medium containerboard products; corrugated cardboard products; carton box products; and coated duplex boards. It also offers capacitor tissue paper; recycled printing and writing paper, such as uncoated wood-free paper and office paper; low and high voltage, ultra-high-voltage transformer coil winding, and heat-resistant insulating paper; and recycled and kraft pulp products. The company generates a good chunk of its revenues from the sale of packaging paper and the rest from sales of printing and writing paper, high-value specialty paper products, and pulp.

The enterprise, which is the largest paper manufacturing group globally in terms of production capacity as well as a leading pulp and paper enterprise, remains committed to pursuing international development, enhancing its production chain and generating additional value for its shareholders.

Nine Dragons Paper (NDGPF), closed Thursday's trading session at $0.49, up 0%, on volume with 00 trades. The average volume for the last 3 months is 2,069 and the stock's 52-week low/high is $0.4635 /$0.9592 .

Specificity (SPTY)

We reported earlier on Specificity (SPTY), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Specificity Inc. (OTCQB: SPTY) is a full-service digital marketing agency that delivers cutting-edge marketing solutions to business-to-business clients as well as business-to-consumer clients.

The firm has its headquarters in Largo, Florida and was incorporated in 2020, on November 25th. It operates as part of the advertising agencies industry, under the communication services sector. The firm serves consumers in the United States.

The company's services include location and search, and criteria targeting services; and device ID extraction and programmatic display services. Its services also include email, automated, retargeting, content, digital production, proximity, print, and voice marketing; social media content, website, brochure, radio commercial, brand standards, logo, and blog creation; Google and Bing display, and Google local service ads; Google and Bing pay per click, targeted print, and text (SMS) campaigns; and search engine optimization and influencer marketing collaborations. On the other hand, its products are based on Enriched AI. They include Amplified Social, which has the ability to create a library of content and have AI post, analyze engagement, create content, among others; and Amplified Email, which automates repetitive tasks and helps eliminate manual burdens. It plans to launch Amplified adtech, in partnership with a leader in the data industry, which will pair smart targeted audiences with AI learning to drive conversions.

The enterprise recently acquired AImplify, a cutting-edge AI-powered solution, a move that will enable them to build an AI tool the market wants and needs and better meet consumer needs, while still opening itself up to new growth and investment opportunities.

Specificity (SPTY), closed Thursday's trading session at $2.87, up 36.6667%, on 3,010 volume with 00 trades. The average volume for the last 3 months is 343,287 and the stock's 52-week low/high is $0.20 /$3.025 .

Verano Holdings Corp. (VRNOF)

QualityStocks, MarketBeat, InvestorPlace, The Street and Early Bird reported earlier on Verano Holdings Corp. (VRNOF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

After the post-pandemic downturn caused many businesses in the cannabis industry to struggle, many marijuana professionals are now predicting a more lucrative 2024. The post-COVID period saw the addition of several more states to America’s nascent marijuana industry, and the country made significant strides in its efforts to legalize marijuana at the federal level. In addition, President Joe Biden issued a mass pardon for marijuana offenders, and his administration has indicated that it is seriously considering rescheduling the controversial plant at the federal level.

Industry professionals are now looking at 2024 with renewed optimism even though the state-legal cannabis industry is likely in for a lot of turbulence. Ed Schmults, CEO of California-based company StateHouse Holdings Inc., says the U.S. Health and Human Services recommendation to the Drug Enforcement Agency (DEA) to move cannabis from Schedule I of the Controlled Substances Act to Schedule III is welcome news, even though it came 10 years late.

Although rescheduling would call for significant levels of legislative effort and time, Schmults is optimistic that the federal government will take the steps needed to move cannabis to Schedule III. He says an implementation timetable of around 12–18 months would be more reasonable than the six-month timeline discussed by some industry players. While descheduling cannabis outright would offer a much better path for the nation’s cannabis industry, Schmultz noted, transferring the drug to Schedule III is a “big step in the right direction.”

David Goubert, president and CEO of multistate marijuana operator AYR Wellness, says that multistate operators will be more focused on their companies’ financial health and will likely prioritize cash-flow generation coupled with lean and efficient operations. He added that if cannabis rescheduling and 280E changes happen as many industry players anticipate, cannabis businesses would start paying fewer annual taxes and would be better equipped to pay down their debt.

The legalization of recreational cannabis in Ohio, Florida and Pennsylvania could also lead to “significant deleveraging” by mid-decade, Goubert says.

Poseidon Asset Management cofounder Morgan Paxhia predicts that next year will be the most exciting and eventful year in the legal cannabis industry’s history. He predicts that while policymakers will reclassify cannabis as a Schedule III substance, “Congressional hijacks” following such a historic legislative development as lawmakers try to take credit could stifle the cannabis industry’s progress and levy a high 14% excise tax on businesses.

However, he notes that the SAFER Banking Act likely won’t make any progress in 2024. Instead, Paxhia expects lawmakers to introduce a ‘=”Garland memo-like protection” alongside rescheduling.

As 2023 draws to a close, many in the cannabis industry, such as Verano Holdings Corp. (CSE: VRNO) (OTCQX: VRNOF), may be fine-tuning their plans to capitalize on any regulatory changes that could be made at the federal level in the coming year or years.

Verano Holdings Corp. (VRNOF), closed Thursday's trading session at $3.71, up 0%, on 262,126 volume with 00 trades. The average volume for the last 3 months is 8.09M and the stock's 52-week low/high is $2.53 /$5.501 .

Workhorse Group Inc. (WKHS)

Green Car Stocks, InvestorPlace, MarketClub Analysis, QualityStocks, Schaeffer's, Kiplinger Today, StocksEarning, MarketBeat, StockMarketWatch, TradersPro, StreetInsider, StockEarnings, Early Bird, The Street, Trades Of The Day, Daily Trade Alert, The Online Investor, GreenCarStocks, TraderPower, TopPennyStockMovers, BUYINS.NET, Zacks, Wealth Insider Alert, Cabot Wealth, InvestorsUnderground, Jason Bond,, PoliticsAndMyPortfolio, StockOodles, The Night Owl, Money Wealth Matters, Profitable Trader Authority, Wealth Daily, Stock Beast, Energy and Capital, The Best Newsletters, Daily Market Beat and The Wealth Report reported earlier on Workhorse Group Inc. (WKHS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Tesla and a slew of automakers recently suffered a major blow in the European market after the German government abruptly ended the country’s electric-vehicle subsidies. With the German coalition government facing an increasingly dire budget crisis, government officials announced the end of the “environmental bonus” program several weeks earlier than planned.

Like several other nations, Germany plans on electrifying its transport network to cut down greenhouse emissions and mitigate climate change. However, electric vehicles are so expensive that the majority of consumers cannot afford to purchase them outright, especially without the aid of government subsidies and incentives.

The German government has now ended its electric vehicle subsidy of up to $4,909 just a few days after it announced that it would not continue the EV subsidy at a reduced $3,273 rate next year. Businesses lost access to the EV subsidy as of Sept. 1, 2023, and it was limited to private drivers for several months until the government finally discontinued it.

Prospective EV drivers in Germany now have no choice but to buy battery electric vehicles (BEVs) at full price. Germany isn’t the first European Nation to limit government subsidies for electric-vehicle purchases.  France limited its subsidies of up to $7,636 to electric cars manufactured in Europe earlier this month, locking out foreign-made models such as the Tesla Model 3, which is manufactured in China. The Model Y still qualifies for the French subsidy because it is manufactured at the Berlin-area facility. Even so, the loss of subsidies will undoubtedly impact Tesla as France and Germany are its largest markets in the EU.

The EV pioneer may also be looking at reduced sales in the United States once Inflation Reduction Act tax credit restrictions kick in on Jan. 1, 2024, and lock out the base Long Range and Rear Wheel drive Model 3. These restrictions would require EVs to source their battery components domestically or from allied nations to qualify for electric-vehicle subsidies.

Tesla currently uses LFP batteries sourced from Chinese battery maker CATL in the base rear wheel drive Model 3, and  the long-range Model 3 uses batteries from South Korean companies that source their raw materials and components from China. While Tesla will work to secure alternative EV battery suppliers, the automaker will most likely see a slump in sales in the near future.

Increased competition in China has also forced Tesla to engage in a price discount war with local automakers. In addition, record interest rates coupled with high prices have depressed EV demand globally, and experts predict further declines in EV demand if EV prices don’t drop significantly.

For companies such as Workhorse Group Inc. (NASDAQ: WKHS) that are looking to tap the European market, things just got a little tighter, and they may need to rely on other strategies to lure buyers.

Workhorse Group Inc. (WKHS), closed Thursday's trading session at $0.375, up 1.4336%, on 11,375,962 volume with 00 trades. The average volume for the last 3 months is 11.57M and the stock's 52-week low/high is $0.345 /$2.60 .

Freeport-McMoRan Inc. (FCX)

MarketClub Analysis, The Street, Schaeffer's, InvestorPlace, Kiplinger Today, SmarTrend Newsletters, StocksEarning, MarketBeat, Barchart, StreetAuthority Daily, Trades Of The Day, Investopedia, StreetInsider, Money Morning, TopStockAnalysts, QualityStocks, Daily Trade Alert, Zacks, Louis Navellier, VectorVest, Trading Markets,, The Growth Stock Wire, ProfitableTrading, Trading Tips, Daily Wealth, The Wealth Report, Top Pros' Top Picks, The Online Investor, StockEarnings, TheStockAdvisors, StreetAlerts, Wall Street Elite, All about trends, DividendStocks, Leeb's Market Forecast, Streetwise Reports, TradingMarkets, Market FN, Early Bird, Market Report, Dividend Opportunities, Investors Alley, TheStockAdvisor, InvestmentHouse, Investor Guide, StockTwits, Wealth Insider Alert, Investment House, Trading Concepts, Money and Markets, INO Market Report, Market Intelligence Center Alert, InvestorGuide, Options Trader Elite, The Best Newsletters, Cabot Wealth, Energy and Capital, Investing Signal, Buttonwood Research, Wyatt Investment Research, Wealth Daily, AnotherWinningTrade, Trade of the Week, The Motley Fool, Darwin Investing Network, Bourbon and Bayonets, Wall Street Daily, Market Authority, Wealthpire Inc., Money Wealth Matters, Investor Update, TradingAuthority Daily, Super Stock Investor, MarketWatch, Street Insider, Profit Confidential, Stock Research Newsletter, AllPennyStocks, InvestorIntel, InvestorsUnderground, Rick Saddler, Uncommon Wisdom, Dynamic Wealth Report, TradersPro, WStreet Market Commentary, Daily Markets, CNBC Breaking News, 24/7 Trader, FNNO Newsletters, Normandy Investment Research, FeedBlitz, Weekly Wizards, MiningNewsWire, Investiv, SmallCapVoice, Weekly Market Strategies, Inside Investing Daily, Investment U, Insider Wealth Alert, Inside Trading, Investing Daily, BUYINS.NET, Daily Profit, Profits Run, StreetAuthority Investor Update, Oakshire Financial, Navellier Growth, The Tycoon Report, ChartAdvisor, Stockhouse, Stock Barometer, Market Intelligence Center, Pennybuster, Greenbackers, Hit and Run Candle Sticks, Average Joe Options, Forbes, StockLockandLoad, TradingPub,, Trader Prep, The Street Report, The Stock Dork, The Night Owl, The Daily Market Alert, Terry's Tips, Taipan Daily, Super Stock Picker, StreetAuthority Financial, Stocks To Watch, Penny Sleuth, StockMarketWatch, InsiderTrades, Stock Beast, SmallCap Network, Shah's Insights & Indictments, Schaeffer’s, PowerRatings Stocks, Penny Stock Buzz, Milestone Capital Growth Portfolio, MicroCap Gems, MarketTamer, Jason Bond, Investors Underground, Investors Daily Edge and StockRockandRoll reported earlier on Freeport-McMoRan Inc. (FCX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Gold prices surged even higher last week after the Federal Open Market Committee issued a surprisingly dovish statement. While the precious metal has performed admirably over the past few weeks, several months of interest rate hikes coupled with a strong dollar depressed gold prices for several months. High interest rates increased the opportunity cost of holding gold bullion and encouraged investors to buy alternative assets that paid interest.

However, hopes of the U.S. Federal Reserve reversing its hawkish stance in 2024 coupled with several geopolitical events, particularly the conflict in Gaza, have elevated gold prices to record levels.

A statement from the Federal Open Market Committee pointing to an additional qualifier reducing the chances for more interest rate hikes has now pushed gold prices even higher. Gold was trading at $1,980 at the start of FOMC day, went up to $2,000 just minutes after the FOMC published its dovish statement and closed the day at $2,024. Furthermore, a lower 2024 outlook for the federal funds rate caused a slight drop in the U.S. dollar and led to a surge of big gold-future purchases.

Gold’s future is looking more bullish after a few rough years, and it will likely attract significant investor demand in 2024. The precious metal should have flourished as the global economy faced the threat of inflation and recession. However, as gold’s performance has mostly been tied to the FOMC thanks to its connection to the U.S. dollar, interest rate hikes and even the indication of future interest rate hikes had a dampening effect on gold prices. The Fed’s historically aggressive interest rate-hike cycle in recent months was extremely rough on the gold market as a result.

Several central banks caused gold prices to rise in 2022 when they embarked on a historic run of gold purchases that lasted into 2023 before gold prices peaked in May. The recent conflict in Gaza caused gold prices to climb even higher as it raised fears of a broader conflict that could affect the oil industry and impact the global economy.

Now that many experts are predicting a possible halt to the Fed’s aggressive rate-hike cycle over the next couple of months, gold could be looking at a relatively lucrative 2024. Without high interest rates and an increasingly valuable dollar pressuring gold prices, the precious metal could take advantage of its safe-haven appeal and attract a significant number of investors looking to protect their money from an increasingly volatile market.

Companies such as Freeport-McMoRan Inc. (NYSE: FCX) could see an uptick in investor interest if gold continues seeing green as it has over the past weeks.

Freeport-McMoRan Inc. (FCX), closed Thursday's trading session at $42.23, up 2.1529%, on 7,032,254 volume with 00 trades. The average volume for the last 3 months is 15.414M and the stock's 52-week low/high is $32.825 /$46.73 .

Tilray Brands Inc. (TLRY)

InvestorPlace, Schaeffer's, StocksEarning, The Street, StockEarnings, MarketClub Analysis, MarketBeat, QualityStocks, Trades Of The Day, Daily Trade Alert, StockMarketWatch, Kiplinger Today, StreetInsider, The Online Investor, Wealth Insider Alert, Market Intelligence Center Alert, BUYINS.NET, Zacks, Investopedia, CFN Media Group, CNBC Breaking News, Early Bird, The Street Report, Daily Profit, INO Market Report, StreetAuthority Daily, Inside Trading, The Rich Investor,, Top Pros' Top Picks, FreeRealTime, InvestmentHouse, Trading For Keeps, Trading Concepts, Eagle Financial Publications, InvestorsObserver Team, Investors Alley, Investment House, Outsider Club, wyatt research newsletter, Wealth Daily, VectorVest, TheTradingReport, The Night Owl, StrategicTechInvestor, Money Morning, Rick Saddler, InvestorsUnderground, AllPennyStocks, MarketClub,, Louis Navellier, Jim Cramer, Jason Bond and Stock Up Featured reported earlier on Tilray Brands Inc. (TLRY), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

For years, Dutch coffee shops have functioned in a system where cannabis sale was permitted, but its growth remained illegal. This led to a lack of transparency for consumers, leaving them unaware of the origins, growers and conditions under which the products they purchased were cultivated. However, that will soon change as the government initiates a marijuana legalization pilot project.

The initial phase of a closed-chain experiment, designed to deliver marijuana from legally sanctioned cultivation to coffee shops commenced on Dec. 15, 2023. The current timeline indicates that two authorized producers will be prepared to supply coffee shops in the final quarter of 2023. This development is substantial enough to initiate the preparatory phase of the pilot program, initially focused on Tilburg and Breda.

Participating coffee shops in Tilburg and Breda will have the opportunity to offer both legally produced marijuana and tolerated products sourced from the illicit market. Two additional producers are anticipated to commence their supply to coffee shops in these cities by February 2024. Tilburg and Breda’s mayors proposed the preliminary phase idea, which was approved by Justice and Security Minister Yeşilgöz-Zegerius and Health, Welfare, and Sports Minister Ernst Kuipers. The aim is to kick-start a modest-scale “experiment with legalized production and sales chain.”

According to reports from, the progress made during the preparatory phase will undergo continuous monitoring. In the event of a significant threat to security or public order, the preparatory phase may be prematurely terminated. The insights gained will be shared with all participating cities, contributing to the refinement of systems and processes for a seamless transition to the subsequent phase.

Expected to last a maximum of six months, the preliminary phase will give way to the transition phase. The earliest commencement for participating cities is projected to be by the end of the Q1 2024. During this stage, coffee shops in these cities will be authorized to offer both black-market and legally cultivated cannabis products. Subsequently, participating coffee shop proprietors will exclusively vend marijuana sourced from regulated crops. Legally produced marijuana will be packaged with a QR code, enabling consumers to access comprehensive information, including details about the product’s origin, cultivation time and the responsible company.

The entire experiment is earmarked for a four-year duration, culminating in a decision on whether to extend its implementation.

For companies such as Tilray Brands Inc. (NASDAQ: TLRY) (TSX: TLRY) with operations in several countries on different continents, the experiment being undertaken in the Netherlands is of great interest because it could eventually open extra market opportunities to tap.

Tilray Brands Inc. (TLRY), closed Thursday's trading session at $2.03, up 1.2469%, on 23,350,704 volume with 00 trades. The average volume for the last 3 months is 30,155 and the stock's 52-week low/high is $1.50 /$3.59 .

WEED Inc.'s (BUDZ)

QualityStocks, Wall Street Mover, Promotion Stock Secrets, TopPennyStockMovers, StreetAuthority Daily, MarketBeat and Jason Bond reported earlier on WEED Inc.'s (BUDZ), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

WEED (OTCQB: BUDZ) is a global cannabis and hemp bioresearch company based in the U.S. focused on the development and application of cannabis–derived compounds for the treatment of human and animal diseases. The company, together with its HEMP BioSciences Inc. (“HEMP”) division, today announced its intention to expand into consumer packaged goods utilizing its rare Landrace strains including Original Panama Red, Acapulco Gold, Red Bud Colombian and Santa Marta Gold.

“HEMP has been issued all required licenses for Industrial HEMP; Growing, Nursery, Harvester, Transporter and Processor licenses under Title 3-Chapter 2-Article 4.1 of The Arizona Department of Agriculture,” said Nicole Marie Breen, COO of HEMP BioSciences. “With the renewal of our hemp licenses, we are now in the process of acquiring a cGMP certification to ensure the highest quality products, while protecting the public in this highly regulated industry. We believe HEMP’s CBD gummies, oils, cremes, tinctures, balms, both broad and full spectrum, will maximize the entourage effects under the strictest manufacturing processes globally.”

To view the full press release, visit

About WEED Inc.

WEED is a leading cannabis company dedicated to delivering exceptional products and experiences to the cannabis consumer market. With operations spanning Israel, Australia and the USA, the company focuses on innovation, quality and sustainability. Through strategic acquisitions and partnerships, WEED aims to shape the future of the cannabis industry.

WEED Inc.'s (BUDZ), closed Thursday's trading session at $0.08008, up 12.1569%, on 35,233 volume with 00 trades. The average volume for the last 3 months is 897,820 and the stock's 52-week low/high is $0.05 /$0.1489 .

The QualityStocks Company Corner

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle ("EV") manufacturer, today announced the delivery of 38 additional Class 3 vehicles to Randy Marion Automotive Group ("RMA" or "Randy Marion") with the company invoicing RMA for $2.5 million. Randy Marion has committed to 1,000 Class 3 vehicles for a total of $63 million, with the majority of the vehicles to be delivered in calendar year 2024. As previously reported, Class 3 production at Mullen's Tunica, Mississippi, facility is planned for 150 vehicles for 2023, with total capacity for Class 3 planned at 3,000 vehicles annually per shift. "The Mullen THREE product is a great offering with 1,000 cubic feet of cargo capacity when upfit with a 14-foot box and offers best-in-class maneuverability," said Brad Sigmon, fleet vice president at Randy Marion Automotive. "Demand is strong for the Mullen's All-Electric product lineup."

To view the full press release, visit

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Thursday's trading session at $14.25, up 17712.5%, on 24,908,756 volume with 00 trades. The average volume for the last 3 months is 836,607 and the stock's 52-week low/high is $6.95 /$10743.75 .

Recent News

FingerMotion Inc. (NASDAQ: FNGR)

The QualityStocks Daily Newsletter would like to spotlight FingerMotion Inc. (NASDAQ: FNGR) .

Over the course of the last 15 months, Lind Partners has been the target of a small group of nefarious individuals spreading misinformation about our position with FingerMotion, Inc. (NASDAQ: FNGR). While our general policy is not to comment on our positions, we felt the need to make this clarification, based on information about our holdings that has already been or will shortly be made public, given the amount of misinformation being shared. On March 23, 2023 , Lind Global Fund II, LP ("Lind Global Fund") disclosed a beneficial ownership of 3,215,296 shares of FingerMotion, Inc, including 2,495,916 shares of Common Stock and 719,380 shares of Common Stock issuable upon the conversion of a convertible note held by Lind Global Fund II LP, representing 6.8% stake in FingerMotion, Inc. on a diluted basis.

FingerMotion Inc. (NASDAQ: FNGR) is an evolving technological company with core competencies in mobile payment and recharge platform solutions in China. FingerMotion is in the process of developing additional value-added technologies to market to users.

Founded in 2016, FingerMotion’s goal is to serve over a billion users in the Chinese market and expand its model to other regional markets. The company has offices in Hong Kong, Shanghai and New York City.

Current Offerings

FingerMotion is analyzing and transforming mobile data to improve the lifestyle of the public through technology and innovation. The company’s current offerings include:

  • Telecommunications Products and Services – FingerMotion’s proprietary universal exchange platform, ‘PigeonHole Integration System (PIS)’, offers seamless integration between telecom operators and online stores. The service platform’s offerings include top up and recharge, data plan, mobile phone, loyalty points redemption and subscription plans. The platform offers reliable and secure transactions, real-time reconciliation, simple integration for partners and efficient settlements.
  • SMS and MMS Services – The integrated platform is registered as FingerMotion’s IP in China and provides a robust back-end control panel for corporate partners to manage their own messaging settings. FingerMotion’s clients range from insurance to financial industries, ecommerce firms, airlines and more. The platform offers competitive pricing for partners and provides quick and efficient review to meet timely marketing initiatives.
  • Big Data Insights – FingerMotion brings Big Data-enabled insurance solutions through its Big Data Insights arm, Sapientus. The company’s strategic partnerships with the largest Chinese telecommunications giants allow access to uncover behavior insights through geolocation and mobile data usage. Its Big Data offerings include risk scoring, precise marketing, simplified underwriting and customized products.
  • Rich Communication Services (RCS) – FingerMotion’s RCS platform will be a proprietary business messaging solution that enables businesses and brands to communicate their services to customers via 5G infrastructure. The company expects its RCS platform to offer a better user experience, more efficiency and cost-effectiveness when compared to other solutions.

Telecommunications and Insurtech Markets

The global telecommunications market was valued at $1.74 trillion in 2019 and is expected to grow at a CAGR of 5% from 2020 to 2027. The steady increase is expected to be driven by the adoption of 5G and the increased popularity of Internet of Things (IoT) applications.

The Chinese telecom market was valued at $254.1 billion in 2017 and is also constantly expanding. The current Chinese telecom market is dominated by three mobile operators – China Mobile, China Unicom and China Telecom, which together are responsible for around 1.6 billion active subscribers (

In addition, the insurtech (insurance technology) market was valued at $2.72 billion globally in 2020 and is expected to grow at a CAGR of 48.8% from 2021 to 2028. The large increase is attributed to the rising use of technology solutions for everyday activities like acquiring insurance coverage (

Through its proprietary platforms and technologies, FingerMotion is uniquely positioned to capitalize on the telecom and insurtech markets’ growth and opportunities.

Management Team

Martin J. Shen is the Chief Executive Officer of FingerMotion Inc. He has over 15 years of experience in senior management roles within entrepreneurial startups and large multinational corporations. He has acquired a wide range of corporate management, financial oversight and operation administration expertise through these roles. In his most recent role, he founded Imperial Distributors (formerly known as AP Martin Pharmaceutical Supplies Ltd.), establishing the company as the preferred choice for distributional support to regional pharmacies throughout Western Canada. Before founding Imperial, Mr. Shen served as the Chief Operating Officer and Chief Financial Officer at Wales and Son Industrial (formerly Weir Minerals), a firm specializing in global delivery and support for mining slurry equipment. He began his career at PricewaterhouseCoopers in Vancouver, with work tours in the tax department in Singapore and the tax audit and advisory group in Hong Kong. Mr. Shen is a U.S. Certified Public Accountant and holds a Bachelor of Science from the University of British Columbia.

Lee Yew Hon is the company’s Chief Financial Officer. From 2006 until November 2020, he was the Chief Financial Officer of Cubinet Interactive Group of Companies, and he also took on the Chief Operating Officer role in 2011. During his tenure, he was instrumental in leading Cubinet and building teams across the Southeast Asia region, setting up financial processes within a short time. Mr. Lee spearheaded the growth of Cubinet to other regions, including Europe, the Middle East and Russia. He received his diploma from Tunku Abdul Rahman College in 1996. He is a Chartered Accountant, a member of the Malaysia Institute of Accountants (MIA) and an Associate Member of the Chartered Institute of Management Accountants, UK (ACMA).

Li Li is the Senior Vice President of FingerMotion. She recently served as Advisor to Shenzhen WuYiKa Technology Co. Ltd., a comprehensive service platform dedicated to online service distribution and payment. The company has become a fast and efficient provider of new media marketing solutions for the mobile internet. She has held high-level management positions with multiple industry names, including Hangzhou JiuYue Information Technology Co. Ltd. and Hangzhou LingXuan Information Technology. Ms. Li started her career in 2004, founding Shanghai ChuangYeZZ Network Technology Co. Ltd. and serving as its Vice President. With the close cooperation of local operators, the company launched SMS, MMS, WAP, mobile JAVA games, Hunan Satellite TV e-magazine and other wireless internet services to meet the rapid development of wireless internet and application requirements. She received her degree from Nanjing Academy of Engineering.

FingerMotion Inc. (FNGR), closed Thursday's trading session at $3.82, up 1.3263%, on 362,966 volume with 00 trades. The average volume for the last 3 months is and the stock's 52-week low/high is $10743.75 /$.

Recent News

Correlate Energy Corp. (OTCQB: CIPI)

The QualityStocks Daily Newsletter would like to spotlight Correlate Energy Corp. (OTCQB: CIPI).

Correlate recently completed solar projects for American Tire Distributors' headquarters and Continental Envelope's manufacturing plant

The projects are a major milestone in Correlate's initiative to showcase a powerful link between sustainability and profitability

The global renewable energy market was valued at $881.7 billion in 2020 and is expected to reach $1,977.6 billion by 2030, growing at a CAGR of 8.4%

To drive shareholder value, Correlate is leveraging a three-pronged strategy enhanced by current investment trends – sell, retain, and acquire

Correlate Energy (OTCQB: CIPI), a growth-oriented distributed energy company, recently announced the successful completion of solar projects for American Tire Distributors' headquarters and Continental Envelope's manufacturing plant, and the commencement of a third project in Reading, Pennsylvania. These projects help further the company's mission to capitalize on America's unstoppable trend toward decentralized energy generation – emphasizing both the affordability and potential profit the company's environmental, social, and governance ("ESG") related energy solutions offer companies and organizations.

Correlate Energy Corp. (OTCQB: CIPI) is a publicly-traded company strategically positioned to capitalize on America’s unstoppable trend toward decentralized energy generation.

The energy grid in the U.S. is insufficient for the booming clean energy trend, and current infrastructure is limiting green energy distribution. Constructing the needed infrastructure to address this demand imbalance will cost billions and be far too slow, positioning decentralized systems, like those on offer from Correlate, in a key position for heightened demand.

Correlate has identified several key economic drivers powering the decentralized energy trend, including:

  1. Real Cost Savings – Customer pays zero money down and gets an instant electrical price discount to current rates.
  2. Massive Project Investment Funding – The International Energy Agency estimates that over one billion dollars per day will be invested in solar energy in 2023.
  3. Consistent Long-Term Incentives – The Inflation Reduction Act is a game-changer, supercharging renewables with $1.2 trillion in tax credits for 10 years of market support.
  4. Robust Customer Demand – Wood Mackenzie expects the U.S. solar industry to nearly triple in size over the next five years.

Correlate’s team of multi-decade experts who have worked with renowned global brands are positioning the company to make the most of this opportunity while consolidating a fragmented industry. Collectively, the team has developed, financed and deployed over $2 billion in clean energy projects to date.

Three-Pronged Strategy

Correlate is leveraging a three-pronged strategy aimed at driving shareholder value:

  1. Sell – Correlate seeks to finance, develop and profitably sell localized clean energy solutions and microgrids to industrial, commercial and residential customers.
  2. Retain – Correlate plans to retain ownership of some of these energy systems and thereby realize ongoing, reliable cash flow.
  3. Acquire – Correlate seeks to acquire proven renewable energy companies in order to exponentially grow earnings per share for investors.

This strategy is enhanced by current investment trends. Clean energy earnings are being sought after by investors. In Q4 2022, the median EBITDA multiple for green energy companies was 12.3x, according to Finerva.

Market Outlook

Over the next decade and beyond, renewable energy growth is expected to come primarily via decentralized systems like those offered by Correlate.
The Inflation Reduction Act enacted in late August 2022 is likewise expected to drive growth for the company by providing new tax incentives that reduce costs for clients and/or elevate returns to investors.

Commercial buildings consume more than 35% of the generated electricity in the U.S. and are underperforming in energy efficiency at every level. These buildings waste energy, emit too much carbon and are too costly for owners and occupants, but retrofits are not happening at the rate or scale needed.

In today’s real estate market, portfolio property owners own most commercial buildings, yet most building efficiency work is focused on single buildings, thereby missing the distinct needs of this owner class which are very different from traditional owner-occupiers. The diverse nature of commercial buildings, combined with technology and performance uncertainty, make simple energy optimization initiatives – which could greatly reduce energy use and improve building value – financially unattractive, resulting in slow adoption rates. CIPI’s financial instruments and software breakdown this issue, known as the ‘split incentive’, unlocking the majority of the addressable market.

A key portion of Correlate’s strategy relates to consolidation of what has been a fragmented industry. By uncovering opportunities to improve efficiencies through strategic M&A activities, the company intends to enhance profitability throughout its operations.

Management Team

Todd Michaels is President and CEO of CIPI and founder of Correlate. He formerly served as Vice President for Innovation at SunEdison and Senior Director Distributed Solar at NRG Energy. He founded Correlate in 2015 and has 16 years of experience in the energy industry. He graduated from Indiana University with a B.S. in Computer Information Systems.

Channing Chen is CFO at CIPI and Correlate Inc. and brings over 16 years of experience in the solar industry as a developer, financier, and business unit leader. He has held executive management roles at Solar Power Partners (acquired by NRG Energy), where he was a founding employee, SunEdison, and NRG Energy (NYSE: NRG). Most recently, Mr. Chen was founder and Managing Partner at Breakaway Energy Partners LLC – a distributed energy financing and market-making platform. To date, Mr. Chen and his teams have raised over $1.5 billion in financing across residential, commercial, and utility scale solar and energy storage projects representing over 400 MWs. He holds a B.A. in Environmental Chemistry from the University of California at San Diego and an MBA from the University of Southern California. He is also an advisor and early-stage investor to several startup companies in the renewable energy space.

Dave Bailey is Chief Revenue Officer of Correlate Inc. With over 15 years of executive sales, supply chain management, and energy efficiency experience, he is responsible for ensuring the success of the National Commercial Sales Unit across multiple regional project teams. Mr. Bailey created and launched the Transformation Services team while at Wesco for its multibillion-dollar Distributed Energy Resource division, formerly Westinghouse. His focus was on IoT-enabled efficiency and plant floor automation-based services. Before that, he spent several years in Global Account Sales Management, with GE Supply as a Program Manager, and is a Commercial Leadership Program graduate. Mr. Bailey received his B.S. in Mechanical Engineering from the University of Kentucky.

Jed Freedlander is the company’s Chief Development Officer. He has a background in infrastructure development and investment and a strong legal, commercial and finance acumen. Mr. Freedlander has a proven track record in leading complex public-private partnership (P3) and energy transactions and is instrumental in driving Correlate’s strategic development initiatives.

Roger Baum is Executive VP Operations at Correlate. With over 20 years of experience at Core Construction, he brings to the company a wealth of knowledge and a strong track record in delivering successful commercial construction projects.

Jason Loyet is Director of Solar Energy for Correlate Inc. He is a cleantech executive with over 20 years of experience leading high growth solar energy and software start-ups. Mr. Loyet is a U.S. Department of Energy SunShot Catalyst award winner for his work building the Solar Site Design technology platform. Before joining the solar energy industry in 2005, he founded and sold two software companies in the streaming media (GlobalStreams) and newspaper publishing (MyCapture) industries. Mr. Loyet currently serves as a Member of the Board of Directors for the Tennessee Solar Energy Industry Association (TenneSEIA).

Correlate Energy Corp. (OTCQB: CIPI), closed Thursday's trading session at $1.4, up 3.7037%, on 9,453 volume with 00 trades. The average volume for the last 3 months is and the stock's 52-week low/high is $0.3501 /$2.35 .

Recent News

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

Lexaria, a global innovator in drug delivery platforms, expects to submit its IND application for its planned U.S. Phase 1b Hypertension Clinical Trial with the FDA within the next 45 days

The HYPER-H23-1 clinical study will build on five successful human clinical trials conducted so far, studying the company's patented DehydraTECH(TM)-processed CBD in an aggregate total of 134 individuals

Lexaria's patented DehydraTECH(TM) "drug delivery platform technology" increases bioavailability, improving the way active pharmaceutical ingredients ("APIs") enter the bloodstream

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced that it anticipates submitting its Investigational New Drug ("IND") application with the U.S. Food and Drug Administration within the next 45 days. The submission will be for its U.S. Phase 1b Hypertension Clinical Trial, whose primary objective will be to evaluate safety and tolerability in hypertensive patients, with secondary objectives including efficacy evaluation in reducing blood pressure together with detailed pharmacokinetic testing (

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has also collaborated with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has been granted patent protection for specific delivery of nicotine, vitamins, NSAIDs, antiviral drugs, cannabinoids and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Thursday's trading session at $1.34, up 3.0769%, on 10,427 volume with 00 trades. The average volume for the last 3 months is and the stock's 52-week low/high is $0.6488 /$3.5953 .

Recent News

D-Wave Quantum Inc. (NYSE: QBTS)

The QualityStocks Daily Newsletter would like to spotlight D-Wave Quantum Inc. (NYSE: QBTS).

D-Wave (NYSE: QBTS) was recently featured in a Forbes contributed article, written by Craig S. Smith, which summarized the top quantum computing companies that are advancing the frontiers of this groundbreaking technology and molding the future landscape of quantum computing. The author also provided a brief overview of the quantum sector and the US government's investment in the technology, noting "The U.S. government spent $2.9 billion on quantum between 2019 and 2022 and is planning on spending more."

"A leader in quantum computing systems, software, and services, D-Wave uses a process called quantum annealing and its systems are employed by some of the world's most sophisticated enterprises, including Google, NASA Ames, and Volkswagen," Smith writes. "Quantum annealing is different from the gate-based quantum computing pursued by most other players in the space but shows promise in solving complex optimization problems at scale. The company focuses on optimization problems to deliver business value."

To view the full article, visit

D-Wave Quantum Inc. (NYSE: QBTS) is a leader in quantum computing systems, software and services focused on delivering customer value via practical quantum applications for problems such as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, fault detection and financial modeling. As the only provider building both annealing and gate-model quantum computers, the company is unlocking commercial use cases in optimization today, while building the technologies that will enable new solutions tomorrow.

D-Wave is a pioneer in quantum computing, with a history of delivering the world’s first commercial quantum computer; the first real-time quantum cloud service; countless hardware and software product and research milestones; and the planned first cross-platform quantum solution which will deliver both annealing and gate-model quantum computers to customers via an integrated platform. Its current commercial product offerings include: Advantage™ (fifth generation quantum computer), Leap™ (quantum cloud service), Launch™ (quantum computing onboarding service) and Ocean™ (full suite of open-source programming tools).

D-Wave’s relentless pursuit of practical quantum computing has resulted in the technology being used today by some of the world’s most advanced enterprises – more than 25 of the Forbes Global 2000 use D-Wave.

D-Wave’s commercial customers include blue-chip industry leaders like Volkswagen, Accenture, BBVA, NEC Corporation, Save-On-Foods, DENSO and Lockheed Martin. The company boasts an extensive IP portfolio featuring more than 200 issued U.S. patents and over 100 peer-reviewed papers published in leading scientific journals.

Founded in 1999, D-Wave is the world’s first commercial supplier of quantum computers. With headquarters and the Quantum Engineering Center of Excellence based near Vancouver, Canada, D-Wave’s U.S. operations are based in Palo Alto, California.

Advantage™ Quantum Computer


With the Advantage™ Quantum Computer, D-Wave has incorporated two decades of experience and over 10 years of customer feedback to create the first and only quantum computer designed for business. The platform features a new processor architecture with over 5,000 qubits and 15-way qubit connectivity. This is 2.5x more connections and more than double the number of qubits than the company’s previous generation quantum computer.

D-Wave’s quantum computers, first located in its facilities in British Columbia, have been available to North American users through its Leap™ quantum cloud service since 2018. It has since introduced new Advantage systems in Julich, Germany, and most recently, Marina Del Rey, California, which marked the availability of the first Advantage quantum computer physically located in the United States.

That new deployment is part of the USC-Lockheed Martin Quantum Computing Center (QCC) hosted at USC’s Information Sciences Institute (ISI), a unit of the University of Southern California’s prestigious Viterbi School of Engineering. Additionally, Amazon Web Services (AWS) and D-Wave announced that the U.S.-based system is available for use in Amazon 2racket, expanding the number to three different D-Wave quantum systems available to AWS users.

Leap Quantum Cloud Service


D-Wave’s customers interface with its systems through the Leap™ quantum cloud service. Leap delivers immediate, real-time access to the company’s Advantage quantum computer and quantum hybrid solver service, all with enterprise-class performance and scalability.

Leap allows developers proficient in Python to get started building and running quantum applications. Through a seamless and secure cloud-based connection, users can easily start solving complex problems of up to 1 million variables and 100,000 constraints.

Using Leap, D-Wave customers have developed quantum hybrid applications for use cases in manufacturing, logistics, financial services, life sciences, materials science, retail and transportation. By eliminating the need to wait hours, days or weeks to get good answers to a broad array of problems, D-Wave is helping businesses move forward.

D-Wave Launch

D-Wave Launch™ is the company’s onboarding platform aimed at helping businesses easily start their quantum journey. Through this program, D-Wave’s team of experts and partners aid enterprises in identifying best use cases for quantum and work with them to develop a proof of concept and production pilot.

From there, the team coordinates with customers to get their hybrid quantum applications up and running, providing ongoing Leap quantum cloud access to ensure the application is operating smoothly and delivering real business value.

Target Verticals

While the potential applications for quantum computing are effectively limitless, D-Wave has identified a number of industry verticals as key areas of focus for its quantum architecture, providing case studies for each. These include:

  • Manufacturing – D-Wave worked with Volkswagen to identify a commercial optimization application, the binary paint shop problem, which was run on D-Wave’s hybrid solver service. The solver outperformed four purely classical methods on problem sizes at commercial scale (N=3,000). In a separate project, similar inputs were tested using a leading ion trap system, which failed to find any commercial solution.
  • Life Sciences – Menten AI makes use of D-Wave quantum computing to assist in the design of novel therapeutic peptides—short strings of amino acids that can act as potent drugs. With the rise of COVID-19, D-Wave’s Advantage system made it possible to identify molecules that might be especially well-suited for binding and inhibiting the related spike protein, producing several promising peptide designs.
  • Finance – Multiverse Computing, a leader in developing quantum solutions for the financial sector, leveraged D-Wave’s hybrid solver service in a collaboration with BBVA, one of the world’s largest financial institutions. Multiverse demonstrated management strategies that far exceeded the granularity of traditional returns in a fraction of the time, helping BBVA identify a low-risk portfolio for investment.

Market Opportunity

The quantum computing total addressable market is projected to grow between $450 billion and $850 billion over the next 15 to 30 years, with between $5 billion and $10 billion of anticipated TAM growth coming in the next three to five years, according to Boston Consulting Group. Driving factors behind this growth include rising investments in quantum computing tech by governments and an increasing number of commercial use-cases.

Forward-thinking organizations see quantum as an opportunity to move ahead of the competition. From finding efficiencies and reducing waste to decreasing time to solution and solving problems abandoned due to complexity, the business value is real. According to data from 451 Research, 40% of large enterprises are already experimenting with quantum computing.

D-Wave is strategically positioned – in an industry with significant barriers to entry – as evident by a decades-long track record serving a roster of blue-chip customers. The company is singularly focused on helping its customers achieve clear value by leveraging quantum computing in practical business applications. With a full stack of systems, software, developer tools and services, D-Wave is working to enable enterprises, governments, developers and researchers to access the power of quantum computing, thereby providing an intriguing opportunity for prospective investors.

D-Wave’s current investor base includes PSP Investments, Goldman Sachs, BDC Capital, NEC Corporation, Aegis Group Partners and In-Q-Tel.

Leadership Team

Dr. Alan Baratz has served as the CEO of D-Wave since 2020. Previously, as Executive Vice President of R&D and Chief Product Officer, he drove the development, delivery, and support of all of D-Wave’s products, technologies, and applications. Dr. Baratz has over 25 years of experience in product development and bringing new products to market at leading technology companies and software startups. As the first president of JavaSoft at Sun Microsystems, he oversaw the growth and adoption of the Java platform from its infancy to a robust platform supporting mission-critical applications in nearly 80 percent of Fortune 1000 companies. He has also held executive positions at Symphony, Avaya, Cisco, and IBM. Dr. Baratz holds a doctorate in computer science from the Massachusetts Institute of Technology.

John Markovich is the company’s CFO. He brings to D-Wave over three decades of experience working with rapidly growing private and public technology companies across all stages of development. Mr. Markovich has directed the finance, accounting, tax, treasury, M&A, legal, operations, customer service, IR, HR, and IT functions for companies ranging from privately held pre-revenue startups to an NYSE-listed Fortune 500 multi-national company with over $1.2 billion in annual revenue. During his career, he has negotiated and closed over 150 debt, equity, M&A, and joint venture transactions exceeding $2.5 billion in value; over a dozen private placements; nearly a dozen M&A transactions; and several international joint ventures. Mr. Markovich holds a BS in Business from Miami University and an MBA from the Michigan State Graduate School of Business.

D-Wave Quantum Inc. (NYSE: QBTS), closed Thursday's trading session at $0.9545, up 1.5426%, on 633,795 volume with 00 trades. The average volume for the last 3 months is and the stock's 52-week low/high is $0.3962 /$3.20 .

Recent News

PaxMedica Inc. (NASDAQ: PXMD)

The QualityStocks Daily Newsletter would like to spotlight PaxMedica Inc. (NASDAQ: PXMD).

In a significant corporate update, PaxMedica (NASDAQ: PXMD) today filed an 8-K with the Securities and Exchange Commission, disclosing its successful compliance with Nasdaq's minimum equity requirements.

Journey Towards Compliance

PaxMedica's compliance journey began on December 6, 2022, when Nasdaq noted its inability to meet the Minimum Market Value of Listed Securities Requirement of $35 million over 30 days. PaxMedica faced potential delisting in June 2023 but successfully appealed and, after a Nasdaq Hearings Panel review, received an exception to remain listed, subject to meeting specific financial criteria.

PaxMedica Inc. (NASDAQ: PXMD) is a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic therapies (APTs) for the treatment of Autism Spectrum Disorder (ASD) and other serious conditions with intractable neurologic symptoms.

The company’s lead programs are focused on ASD, for which there are currently no approved pharmacologic treatments that target its cause and symptoms. Currently used treatments only address the symptoms of the condition, rather than targeting the pathophysiology itself.

PaxMedica is on a promising path to address these unmet medical needs, bringing hope to millions. Anti-purinergic therapies target the excess production of purines in cells. An overexpression of purines can offset homeostasis and result in an overproduction of cellular adenosine triphosphate, the main energy molecule in all living cells.

The company is headquartered in Tarrytown, New York.

Product Pipeline

PaxMedica is building a robust pipeline of products targeting ASD and related neurodevelopmental conditions. The company’s lead product in development may help eliminate, reduce or modulate some of the more troublesome aspects of ASD. That would open the potential for people with autism to integrate their behavior with others more successfully and improve their lives.

PaxMedica’s lead programs, PAX-101 and PAX-102, utilize the company’s proprietary source of suramin sodium, a broadly acting anti-purinergic therapy that has been known for over 100 years. Its current pipeline includes:

  • PAX-101 (IV Suramin) for ASD – PAX-101 completed a Phase 2B study for ASD in 2021. Suramin is a broadly acting APT and has reported positive results from a dose range study. The results of PaxMedica’s Phase 2B study, which targeted 52 subjects across six sites in South Africa, were presented to AACAP in October 2021.
  • PAX-102 (Intranasal Suramin) – PaxMedica has developed a proprietary intranasal formulation of suramin that is currently being evaluated in ASD and other neurodevelopmental conditions.
  • PAX-101 for HAT – Given suramin’s historical use as a treatment for Human African Trypanosomiasis (HAT), or African Sleeping Sickness, the company is also developing PAX-101 as a treatment for HAT. PaxMedica’s most advanced program is the pursuit of PAX-101 for early-stage East African HAT.
  • Selective APTs – PaxMedica has conducted several preclinical studies to evaluate other APTs that are more selective to specific purinergic receptors and may offer additional benefits over suramin.

Market Opportunity

According to a report by Fortune Business Insights, a leading global market research company, the global ASD therapeutics market was estimated at $1.93 billion in 2022 and is projected to grow from $2.01 billion in 2023 to $3.42 billion by 2030, a CAGR of 7.9% over the forecast period. As there is no current treatment for the core symptoms of autism, PaxMedica believes the addressable market for PAX-101, if approved, could greatly exceed these forecasts.

Autistic disorder, Asperger’s Syndrome and Pervasive Development Disorder are the three main types of ASD, affecting millions of people globally. A 2020 report by the U.S. Centers for Disease Control & Prevention estimated that one in 36 children in the U.S. have been diagnosed with autism disorder.

Several factors are expected to contribute to market growth prospects. A growing prevalence of the condition globally and rising awareness coupled with available treatment options are key factors expected to drive ASD therapeutics market growth during the forecast period. Growing investment in R&D to find effective treatments is also expected to fuel global market growth.

Management Team

Howard Weisman is Chairman and CEO of PaxMedica. He has been a founder and CEO of several specialty pharma and medical device companies. Most recently, he was executive chairman and co-founder of Sofregen, a biotech company. He also served as CEO and president of Seventh Sense Biosystems, a medical device development company. He also was founder, chairman and CEO of EKR Therapeutics, a specialty pharmaceutical company, and founder and COO of ESP Pharma, a company focused on cardio and neurovascular products. He has a bachelor’s degree in chemistry from Rutgers University.

David Hough, M.D., is Chief Medical Officer at PaxMedica. He is a neuroscience clinical development consultant who previously served as vice president at Janssen Research and Development and in various leadership roles over 17 years. Most recently, he was the compound development team leader for SPRAVATO® for treatment-resistant depression. Prior to that, he was the schizophrenia disease area leader. He played a pivotal role in the development programs for oral INVEGA®, INVEGA SUSTENNA® and XEPLION® for schizophrenia. He is a graduate of West Point and is board certified in psychiatry.

Stephen Sheldon is COO and CFO at PaxMedica. He has served as CEO of Thailand-based specialty healthcare company Indochina Healthcare Co. Ltd. since 2015. Previously, he was a consultant for PricewaterhouseCoopers Healthcare Advisory in the Chicago office. He was responsible for developing specialty pharmacy patient programs, strategy development for specialty products and compliance programs. He has an MBA from Thunderbird School of Global Management and a bachelor’s degree in computer science and visual arts from Bowdoin College.

PaxMedica Inc. (NASDAQ: PXMD), closed Thursday's trading session at $0.8046, up 5.0392%, on 605,067 volume with 00 trades. The average volume for the last 3 months is and the stock's 52-week low/high is $0.6384 /$69.19 .

Recent News

Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF)

The QualityStocks Daily Newsletter would like to spotlight Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF).

Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF), a leading developer of rare earth element ("REE") processing technology, has completed the third and final stage of planned commissioning procedures at the company's RapidSX(TM) Commercial Demonstration Plant; the company has also begun the U.S. Department of Defense ("DoD") demonstration program. The demo plant is situated at Ucore's 5,000-square-foot RapidSX Commercialization and Demonstration Facility in Kingston, Ontario; the facility is operated by Ucore's commercialization partner, Kingston Process Metallurgy Inc. "Since early this year, the company has been testing, adjusting and optimizing its 52-stage demo plant to meet its RapidSX commercialization and demonstration deployment objectives in Louisiana," said Ucore vice president and chief operating officer Mike Schrider, PE, in the press release. "Ucore is very pleased to announce the completion of commissioning procedures with its third and final mixed REE chemical concentrate and the commencement of its U.S.–DoD demonstration program. The objectives of this program are to establish a direct techno-economic comparison between conventional solvent extraction [‘CSX'] and RapidSX for separating heavy and light rare earth elements and to establish RapidSX technology for commercial deployment in North America."

To view the full press release, visit

Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) is a critical metals (“CM”) separation technology company executing an ESG-centered plan toward establishing a comprehensive North American critical metals supply chain. The company has developed a transformative commercial-ready technology, RapidSX™, for separating and purifying critical metals. Ucore intends to deploy this technology in pursuit of a CM supply chain independent of China for Western original equipment manufacturers (“OEMs”), most notably in the automotive and renewable energy industries.

Ucore’s vision is to become a leading advanced technology company providing best-in-class metal separation products and services to the mining and mineral extraction industry. Its initial focus is on processing heavy and light rare earth elements (“REEs”), disrupting a supply chain that is dominated by China.

China currently controls about 80% of the world’s access to REE mining projects and over 90% of the world’s REE processing capabilities, and it produces about 95% of the goods containing REE components.


Ucore is working to scale Western supply needs by establishing REE separation and rare earth oxide (“REO”) production capabilities in cooperation with strategic upstream supply and downstream offtake partnerships. The company, along with its industry partners, aims to unlock access to Western REEs for current consumer, energy, manufacturing and military sectors.

By 2025, Ucore expects to commercially separate U.S.-friendly sources of REEs and supply OEMs with REOs required to produce rare earth permanent magnets (“REPMs”) – the essential component of electric motors and generators required to support the world’s transition to electrification and sustainable energy sources.

The company intends to contribute to this initiative through the near-term development of a heavy and light rare-earth processing facility in Louisiana and subsequent development of Strategic Metals Complexes (SMCs) in Alaska and Canada, as well as through the longer-term development of its 100%-owned Heavy Rare Earth Element (HREE) mineral resource property at Bokan Mountain on Prince of Wales Island, Alaska.

Ucore is headquartered in Halifax, Nova Scotia.

Projects & Technology

RapidSX™ Demonstration Plant

The Kingston, Ontario, RapidSX™ Demonstration Plant commissioning process is underway. Once commissioned, the plant is designed to demonstrate the commercial capabilities of the RapidSX technology platform.

The RapidSX demo plant will show:

  • The techno-economic advantages of the RapidSX technology platform
  • The processing of tens of tons of heavy and light mixed rare earth element concentrates in a simulated production environment
  • The platform’s ability to operate for thousands of semi-continuous run-time hours
  • Production of high-purity NdPr, praseodymium, neodymium, terbium and dysprosium rare earth elements for early OEM product qualification trials

The demo plant is located within Ucore’s 5,000-square-foot RapidSX Commercialization and Demonstration Facility and is run by its laboratory partner, Kingston Process Metallurgy Inc. (“KPM”).

RapidSX™ Technology

Innovation Metals Corp., acquired by the company in 2020, developed the RapidSX separation technology platform with early-stage assistance from the United States Department of Defense, later resulting in the production of commercial-grade, separated rare earth elements at pilot scale.

RapidSX combines the time-proven chemistry of conventional solvent extraction (SX) with a new column-based platform that significantly reduces time to completion and plant footprint, as well as potentially lowering capital and operating costs. SX is the international REE industry’s standard commercial separation technology and is currently used by all REE producers worldwide for bulk commercial separation of both heavy and light REEs.

Utilizing similar chemistry to conventional SX, RapidSX is not a “new” technology, but it represents a significant improvement on the well-established, well-understood, proven conventional SX separation technology preferred by REE producers.

Strategic Metals Complex

Ucore, engineering partner Mech-Chem Associates Inc. and KPM are developing the full-scale engineering for the company’s first Strategic Metals Complex (SMC). The SMC is a planned REE separation and rare earth oxide production plant slated to commence construction in Louisiana in 2023. It is scheduled to initially process 2,000 tons of total rare earth oxides by the end of 2024, increasing to 5,000 tons in 2026.

The company has three initial U.S.-friendly feedstock agreements in place for the Louisiana complex, along with multiple developing offtake agreements. It received a C$16 million+ incentive package offer from Louisiana Economic Development to support construction of the SMC.

Bokan-Dotson Ridge REE Deposit

Ucore has invested over C$35 million to establish and validate the Bokan-Dotson Ridge resource in preparation for mine design and permitting. Initial drilling is complete, and a Preliminary Economic Assessment has been issued. Next steps for the project include a feasibility study, detailed mine design and permit acquisition. The project can be “near shovel ready” for construction in less than 30 months after receipt of the next stage of development funding.

Market Opportunity

According to a report by Grand View Research, the global rare earth elements market was valued at $2.8 billion in 2018 and is forecast to reach a value of $5.6 billion by 2025, achieving a CAGR of 10.4% during the period. Market growth is driven by increasing demand for these elements in the manufacturing of magnets and catalysts for the automotive industry. Rising demand for electric vehicles to reduce CO2 emissions is expected to propel the use of permanent magnets in the production of EV batteries.

China is the major producer and consumer of REEs. To maintain self-sufficiency and to meet future demand, China has been raising the export tariffs on rare earth elements shipped to various countries, including the U.S., Japan, India, Brazil and the European Union. This led to the current supply-demand gap in these countries, as they rely on imports from China.

China reduced the exports of REEs by 72% in the second half of 2010 to preserve its reserves of these elements and continues to export REEs at reduced levels, thereby affecting industries such as automotive, oil and gas, and electronics, which require an ample amount of rare earth elements.

Management Team

Pat Ryan, P.Eng., is Chairman and CEO of Ucore Rare Metals. He began as a director with the company when he developed a heightened interest in critical metals. Before joining Ucore, he founded and led a multimillion-dollar automotive OEM design and lean manufacturing company. His understanding of complex supply chains across international markets has led to a prime positioning as the global auto industry transitions to vehicle electrification. He holds a Bachelor of Engineering degree from Dalhousie University.

Peter Manuel is Vice President and CFO of Ucore. Prior to joining the company, he practiced as a Chartered Accountant for more than 17 years, providing consulting services to companies in a range of industries, with a focus on the financial services and resource sectors. He spent 10 years in England and Ireland providing assurance, strategic planning, corporate finance and other consulting services to a portfolio of both public and private entities. He holds a Bachelor of Commerce Degree from Dalhousie University.

Michael Schrider, MEng, P.E., is Vice President and COO of Ucore. He is a multidisciplinary engineer who has been involved in manufacturing, engineering and managing complex structural and mechanical systems projects since 1989. He was the Founder, President and Chief Engineer of Schrider & Associates and Alton Bay Design, both engineering services firms. He holds a bachelor’s degree in naval architecture and marine engineering from the University of New Orleans and a master’s degree in mining, geological and geophysical engineering from the University of Arizona.

Mark MacDonald is Vice President of Investor Relations at Ucore. He has over 25 years of experience implementing award winning business development and marketing programs at regional and national levels. As Vice President of Sales, he was responsible for Mediapro Communication’s growth as AT&T Canada’s leading B2B sales partner. He subsequently became Atlantic Regional Vice President of AT&T Canada Corp. He holds a Bachelor of Commerce degree from Dalhousie University.

Ucore Rare Metals Inc. (UURAF), closed Thursday's trading session at $0.67215, up 13.654%, on 82,647 volume with 00 trades. The average volume for the last 3 months is and the stock's 52-week low/high is $0.395 /$1.15 .

Recent News

Fathom Nickel Inc. (CSE: FNI) (FSE: 6Q5) (OTCQB: FNICF)

The QualityStocks Daily Newsletter would like to spotlightFathom Nickel Inc. (CSE: FNI) (FSE: 6Q5) (OTCQB: FNICF).

Fathom Nickel CEO Ian Fraser joined Steve Darling from Proactive provided a comprehensive overview of the company's notable achievements throughout the year 2023. Furthermore, he eloquently outlined the company's ambitious and promising plans for the upcoming year, 2024. Fraser's positive outlook was palpable as he expressed his satisfaction with the significant strides Fathom Nickel had made in the past year and his unwavering optimism for the road ahead. One of the major highlights of Fathom Nickel's journey in 2023 was their dedicated focus on the Gochager Lake project. Fraser emphasized that the company had made substantial advancements in comprehending the intricacies of the project, particularly in terms of understanding the vertical shoots of higher-grade mineralization.

Fathom Nickel Inc. (CSE: FNI) (FSE: 6Q5) (OTCQB: FNICF) is a Canadian natural resource development and exploration company that targets high-grade nickel sulfide discoveries for use in the rapidly growing global electric vehicle (EV) market. The company has a portfolio of two high-quality exploration projects located in the prolific Trans Hudson Corridor in Saskatchewan.

Led by a management team with more than 100 years of combined mining and exploration experience, Fathom believes in a continuing bright outlook for nickel and its increasing use in the manufacturing of batteries needed for energy storage in the high-growth renewable energy and EV industries. The company’s modern approach to exploration has yielded significant new nickel discoveries.

Fathom is headquartered in Calgary, Alberta.


The Albert Lake Project

The Albert Lake Project comprises 90,460 hectares of lands located in north-central Saskatchewan, with over 80,000 hectares currently unexplored. The project is host to the historic Rottenstone Mine, a high-grade, open pit nickel sulfide past producer that was active from 1965 to 1969 and yielded ~26,000 tonnes of 3.3% Ni, 1.8% Cu, and >9 g/t Pd-Pt+Au.

The geological setting of the Albert Lake Project is within the Trans Hudson Orogeny (Corridor), which is host to numerous world-class nickel mining camps including the Thompson Nickel Belt (currently operating with more than 5 billion pounds of nickel produced since 1959), Lynn Lake (past producer) and Raglan Nickel Belt (currently operating with more than 39,000 tons of nickel produced in 2020).

The project is fully permitted. Exploration plans for 2024 include drilling a high-priority target located approximately 2km south of the historic Rottenstone Mine along with drilling other high-priority targets. Additional soil geochemistry, surface geophysical programs and geological mapping and prospecting will be performed during the summer field season.

The Gochager Lake Project

The Gochager Lake Project in northern Saskatchewan, also in the prolific Trans Hudson Corridor, was recently expanded through the addition of the contiguous Watt’s Lake property and direct staking, bringing its total land area to 22,620 hectares.

The Gochager Lake property is host to a historic resource defined by drilling in 1966-1967 consisting of 4.2 M tons grading 0.29% Ni and 0.08% Cu. Recent drilling by Fathom has defined multiple very robust off-hole borehole electromagnetic (BHEM) responses in eight of nine holes drilled in 2023 and three historic drill holes probed. There is very strong evidence of multiple, high-grade nickel-copper-cobalt steeply oriented chutes within the historic Gochager Lake Deposit.

Prior to Fathom exploration in 2023 and since 1970, exploration at the property has been limited to small drill programs in 1989-1990 and 2018. Exploration plans for 2024 include expanded surface geophysical programs, drilling and continued BHEM surveys to expand tons and increase the grade of the historic Gochager Lake deposit. Summer exploration will consist of soil geochemistry, mapping, prospecting and additional surface geophysical programs focused on identifying other Gochager-like deposits within the current land package.

Market Opportunity

Nickel plays a crucial role in clean energy technologies, and that is expected to cause demand to well outstrip supply for the foreseeable future.

With an annual market value of around $35 billion, nickel demand is projected to rise due to its intensive use in lithium-ion batteries used to power EVs. However, new discoveries of nickel sulfide deposits (currently the most reliable source for battery-grade class 1 nickel) have been rare, which could constrain class 1 nickel supply in the coming years.

According to Deloitte’s global EV forecast, total EV sales will grow from 2.5 million in 2020 to 11.2 million in 2025, reaching 31.1 million by 2030 and representing approximately 32% of the total market share for new car sales. Over the next 10 years, the EV market is projected to see a CAGR of 29%, with increased demand for nickel expected to be comparable.

Management Team

Fathom Nickel has assembled a best-in-class leadership team consisting of highly qualified industry professionals with deep knowledge and understanding of the mineral exploration industry and capital markets.

Ian Fraser, P.Geo., is CEO, VP Exploration and Co-Founder of Fathom Nickel. He has more than 35 years of experience in mineral exploration, as well as managing and implementing exploration projects in Canada and internationally. His experience includes resource interpretation and development of the Casa Berardi Gold Mine and Komis Gold Mine, as well as the Cisneros Gold Mine in Colombia.

Doug Porter, CPA, CA, CBV, is President, CFO and Director of Fathom Nickel. He is a senior financial and accounting executive with specific emphasis in resource company management. His career includes positions with Elan Coal Ltd., Altitude Resources Ltd. and StimWrx Oilfield Services Ltd.

Fathom Nickel Inc. (OTCQB: FNICF), closed Thursday's trading session at $0.0908, up 8.2241%, on 6,000 volume with 00 trades. The average volume for the last 3 months is and the stock's 52-week low/high is $0.025 /$0.2634 .

Recent News

Sekur Private Data Ltd. (CSE: SKUR) (OTCQB: SWISF) (FRA: GTD0)

The QualityStocks Daily Newsletter would like to spotlight Sekur Private Data Ltd. (CSE: SKUR) (OTCQB: SWISF) (FRA: GTD0).

Sekur expects to launch its Sekur Enterprise suite in mid-January 2024 to offer comprehensive security features designed to meet enterprises' demands worldwide

Sekur Enterprise will include SekurMessenger for Enterprise and SekurRelay

Sekur recently signed distributor agreements in Jordan and Qatar, including Beyond Limits Programs and Electronics ("BLPE"), a Qatari corporation

Sekur Private Data (CSE: SKUR) (OTCQB: SWISF) (FRA: GDT0), a leading Swiss-hosted secure and private communications platform, recently announced significant developments that will revolutionize the world of private and secure communications – including the launch of Sekur Enterprise plus a signed distribution agreement with Qatar.

Sekur Private Data Ltd. (CSE: SKUR) (OTCQB: SWISF) (FRA: GTD0) is a Cybersecurity and Internet privacy provider of Swiss hosted solutions for secure and private communications. The company distributes a suite of encrypted e-mails, secure messengers and secure communication tools. Sekur Private Data Ltd. sells its products through its own website at, approved distributors, and telecommunications companies. Sekur Private Data Ltd. serves consumers, businesses and governments worldwide.

Customer information is completely confidential and safely stored in Switzerland using military grade security. All data, whether physical, network-based or encryption security, is stored in bank-approved, state-of-the-art ISO-certified data centers used by Swiss and global banks and most United Nations organizations, as well as many corporations and governmental organizations. All user data is protected by the Swiss Federal Data Protection Act and the Swiss Federal Data Protection Ordinance, which offer some of the strongest privacy protection in the world for both individuals and organizations.

The company owns 100% of its own infrastructure and, unlike its competitors, does not rely on third party cloud services like Amazon Web Services, Microsoft Azure Cloud or Google cloud infrastructure.

Sekur Private Data has chosen Switzerland to locate its data storage because of the country’s neutrality, independence, strong privacy laws, long standing political stability and excellent international relations. Switzerland is also home to several large multinational corporations and is ranked as having one of the strongest and most competitive economies in the world.

The company is headquartered in Toronto, Ontario.


Sekur Private Data distributes a privacy communications suite offering encrypted and private email, the only Swiss-hosted privacy VPN, and a secure and private messaging application. All solutions cater to consumers, SMBs, enterprises and governments.

  • SekurMail® is an encrypted email service offering a private, safe and powerful tool to communicate with everyone, either within the Sekur ecosystem or outside. SekurMail protects personal information and communications from being accessed by unauthorized parties. Its encryption and other security measures prevent messages from being intercepted, modified or tampered with, either in transit or while stored. SekurMail empowers the client to access information and communicate with anyone in the world, regardless of geographical or political barriers.
  • SekurVPN® creates a secure, encrypted connection between the client’s device and the Internet, giving clients access to the web safely and privately by routing their connections through a server and hiding their online actions. All the data sent and received is hidden from prying eyes. This includes the clients’ Internet Service Providers, as well as potential hackers and even government surveillance agencies. It can also help clients bypass geographical restrictions and censorship.
  • SekurMessenger® is a Swiss-hosted private and secure messaging communications app providing secure and private chat, self-deleting chat, voice recording and file transfer via any mobile device, tablet or desktop computer. Communications are transmitted only within secure servers. It’s designed for organizations that need to protect their flow of information and secure their communications with customers and partners. SekurMessenger is designed to provide military-grade encryption and privacy by ensuring that only the sender and intended recipient can read the messages exchanged. It works for both licensed users of the app and intended message recipients who do not have the app.

Market Opportunity

An analysis from ReportLinker forecasts that the global cybersecurity market will grow from an estimated $173.5 billion in 2022 to $266.2 billion by 2027, recording a CAGR of 8.9% for the period.

The increased number of data breaches worldwide, the ability of malicious actors to operate from anywhere in the world, the links between cyberspace and physical systems and the difficulty of reducing vulnerabilities and consequences in complex cyber networks are some factors that are driving cybersecurity market growth, according to the report.

The global data privacy software market was estimated to be worth $1.68 billion in 2021 and is expected to grow from $2.36 billion in 2022 to $25.85 billion by 2029, achieving an eye-popping 40.8% CAGR during the forecast period, according to a Fortune Business Insights report titled ‘Data Privacy Software Market 2022-2029’.

The widespread shift toward remote working culture, evolving government data privacy regulations and the rapidly increasing adoption of Internet-of-Things devices are among the major factors propelling market growth, per the report.

Management Team

Alain Ghiai is founder, CEO and Director at Sekur Private Data. He also founded GlobeX Data S.A. (GDSA) in 2007 and has served as Director and CEO since then. He founded GlobeX Data Inc. (GlobeX US) in August 2012 and has served as Director and CEO since that time. He attended the California College of Arts in San Francisco, where he earned a Bachelor of Architecture. He has over 15 years of experience in the software industry and was instrumental in taking Sekur Private Data public in July 2019.

Scott Davis, CPA, CGA, is CFO at Sekur Private Data. He is also a partner at Cross Davis & Company LLP Chartered Professional Accountants. His experience includes CFO positions at several companies listed on the TSX Venture Exchange. He spent four years at Appleby as an Assistant Financial Controller. Prior to that, he spent two years at Davison & Company Chartered Professional Accountants as Auditor, five years with Pacific Opportunity Capital as Accounting Manager and two years at Jacobson Soda and Hosak, Chartered Professional Accountants. He obtained his CPA, CGA in 2003.

Learn more about the company’s management team by visiting its corporate page.

Sekur Private Data Ltd. (OTCQB: SWISF), closed Thursday's trading session at $0.06625, up 5.1587%, on 47,414 volume with 00 trades. The average volume for the last 3 months is and the stock's 52-week low/high is $0.027 /$0.1576 .

Recent News

Longeveron Inc. (NASDAQ: LGVN)

The QualityStocks Daily Newsletter would like to spotlight Longeveron Inc. (NASDAQ: LGVN) .

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome ("HLHS"), Alzheimer's disease and Aging-Related Frailty, has announced a $2.36 million registered direct offering. The company entered into a definitive agreement for the issue and sale of 1,355,301 shares of common stock, priced at $1.745 per share. In addition, the company announced a concurrent private placement comprised of the issue and sale of unregistered warrants to purchase up to 1,355,301 additional shares common stock. According to the announcement, the warrants will have an exercise price $1.62 per share and will be exercisable upon issuance; the term of the warrants will be five and one-half years from the date of issue. Longeveron anticipates the offering, which is subject to typical closing conditions, will close on or about Dec. 22, 2023. The company plans to use the net proceeds from the offering for working capital and general corporate purposes. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

To view the full press release, visit

Longeveron Inc. (NASDAQ: LGVN) is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. The Company’s research and therapies are aimed at improving the outcome of infants born with a life-threatening heart condition, as well as improving the healthspan for the aging population – the number of years a person is expected to live in relatively good health, free of chronic disease and disabilities of aging, with function and ability to perform activities of daily living.

Longeveron is involved in clinical trials in the following indications: Hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty.

The Company’s philosophy revolves around the idea that regenerative medicine may hold the potential to improve certain rare medical conditions and contribute to healthy aging. While there has been a remarkable rise in life expectancy over the last century due to medical and public health advancements, this increase in longevity has not been paralleled by the number of years a person is expected to live in relatively good health, free of chronic disease and disabilities of aging.

Longeveron’s lead investigational product is Lomecel-B™, an allogeneic Medicinal Signaling Cell therapy product isolated from the bone marrow of young, healthy adult donors. As humans age, they experience a decrease in immune system function, a decline in blood vessel functioning, chronic inflammation, and other issues. Clinical data has suggested that Lomecel-B™ may address these conditions through multiple mechanisms of action (MOA) that simultaneously target key aging-related processes.

The Company is headquartered in Miami, Florida.


Lomecel-B™ is being evaluated in multiple clinical trials for aging-related chronic diseases and other life-threatening conditions under U.S. FDA-approved Investigational New Drug applications. Lomecel-B™ has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas.

The drug is made from special living cells called Medicinal Signaling Cells (MSCs) that are isolated from fresh bone marrow tissue that has been donated by adult donors aged 18 to 45. Once the MSCs have been isolated from the fresh bone marrow through a careful selection process, the cells are culture-expanded (allowed to replicate under controlled laboratory conditions) into the billions using specialized techniques and processes. After a specific number of expansion cycles, called “passages,” the cells are harvested, separated into specific doses (e.g., 50 million cells), and cryopreserved until future use.

These cells have been shown to have characteristics that allow them to be transplanted from a donor to host without triggering a harmful immune response in the recipient, and they can be administered on an outpatient basis in as little as 40 minutes after thawing. Because of these characteristics, Lomecel-B™ is considered an “off-the-shelf” product.

In some trials, such as for Alzheimer’s disease and Aging-related Frailty, Lomecel-B™ is administered via peripheral intravenous infusion, while, in the Company’s HLHS trial, Lomecel-B™ is administered via direct injection into the heart tissue.

Market Opportunity

Longeveron estimates the potential market size for Lomecel-B™ in the treatment of HLHS to be up to $1 billion annually, globally.

U.S. patients suffering from Aging-related Frailty are estimated using U.S. Census Bureau statistics to be approximately 8.1 million. That population potentially represents a market for Lomecel-B™ of between $4 billion and $8 billion globally per year, according to Company estimates.

Additionally, the Alzheimer’s Association puts the number of Americans with that disease at 5.1 million, highlighting another potentially addressable market for Lomecel-B™, that’s worth $5 billion to $10 billion annually.

Management Team

Wa’el Hashad is CEO of Longeveron. He has more than 35 years of experience in the pharmaceutical and biotech industries. He has launched several successful brands in the U.S. and worldwide markets. Prior to joining Longeveron, he was president and CEO of Avanir Pharmaceuticals. Before Avanir, he was the chief commercial officer of Seres Therapeutics. He also has held senior leadership positions at Amgen, Boehringer Ingelheim, and Eli Lilly and Company. He holds a bachelor’s degree in pharmacy from Cairo University and an MBA from the University of Akron.

Joshua M. Hare, M.D., FACC, FAHA, is Co-Founder, Chief Science Officer and Chairman of Longeveron. He is a double board-certified cardiologist and is the founding director of the Interdisciplinary Stem Cell Institute at the University of Miami’s Miller School of Medicine. He is a recipient of the Paul Beeson Physician Faculty Scholar in Aging Research Award and is an elected member of the American Association of Physicians and The American Society for Clinical Investigation. He is also an elected Fellow of the American Heart Association. He received a bachelor’s degree from the University of Pennsylvania and his M.D. from The Johns Hopkins University School of Medicine.

Lisa Locklear is CFO at Longeveron. She previously served as the senior vice president and CFO for Avanir Pharmaceuticals. Prior to Avanir, she held senior financial roles at GSN Games, CoreLogic, Ingram Micro, the Walt Disney Company, and Price Waterhouse, with assignments in Paris and London. She holds a bachelor’s degree in plant science from the University of California, Davis, and an MBA from the University of California, Irvine. She is a licensed CPA (inactive) and is a member of the American Institute of Certified Public Accountants, the California Society of CPAs, and Financial Executives International.

Dr. Nataliya Agafonova, M.D., is the Chief Medical Officer at Longeveron. She previously served as clinical development lead, senior medical director, and product development chair at Otsuka Pharmaceuticals. Before that, she was the clinical development lead and senior medical director at Bristol-Myers Squibb. She previously held senior leadership positions at Ardea Bioscience, Biogen, Amgen, and Genzyme Corporation. She earned an M.D. from the Ukrainian National Medical University and completed her internal medicine residency at Kharkov State University Hospital in Ukraine.

Certain statements in this corporate profile that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which reflect management’s current expectations, assumptions, and estimates of future operations, performance and economic conditions, and involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the statements made herein. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as “believe,” “expects,” “may,” “looks to,” “will,” “should,” “plan,” “intend,” “on condition,” “target,” “see,” “potential,” “estimates,” “preliminary,” or “anticipates” or the negative thereof or comparable terminology, or by discussion of strategy or goals or other future events, circumstances, or effects. Factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statements in this release include, but are not limited to, statements regarding the offer and sale of securities, the terms of the offering, about the ability of Longeveron’s clinical trials to demonstrate safety and efficacy of the Company’s product candidates, and other positive results; the timing and focus of the Company’s ongoing and future preclinical studies and clinical trials and the reporting of data from those studies and trials; the size of the market opportunity for the Company’s product candidates, including its estimates of the number of patients who suffer from the diseases being targeted; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy and therapeutic effects of the Company’s product candidates; the Company’s ability to obtain and maintain regulatory approval of its product candidates in the U.S., Japan and other jurisdictions; the Company’s plans relating to the further development of its product candidates, including additional disease states or indications it may pursue; the Company’s plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and its ability to avoid infringing the intellectual property rights of others; the need to hire additional personnel and the Company’s ability to attract and retain such personnel; the Company’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company’s need to raise additional capital, and the difficulties it may face in obtaining access to capital, and the dilutive impact it may have on its investors; the Company’s financial performance and ability to continue as a going concern, and the period over which it estimates its existing cash and cash equivalents will be sufficient to fund its future operating expenses and capital expenditure requirements. Additionally, Longeveron makes no assurance that any public offering of its securities as described herein will occur on the timelines, in the manner or on the terms anticipated due to numerous factors. Further information relating to factors that may impact the Company’s results and forward-looking statements are disclosed in the Company’s filings with the Securities and Exchange Commission, including Longeveron’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission on March 14, 2023 and its Quarterly Report on Form 10-Q for the second quarter of 2023 filed with the SEC on August 11, 2023. The forward-looking statements contained in this corporate profile are made as of the date of this corporate profile, and the Company disclaims any intention or obligation, other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Investor Contact
Mike Moyer
LifeSci Advisors
Tel: 617-308-4306

Date prepared: August 31, 2023

Longeveron Inc. (NASDAQ: LGVN), closed Thursday's trading session at $1.25, up -22.8395%, on 1,202,523 volume with 00 trades. The average volume for the last 3 months is 376,130 and the stock's 52-week low/high is $1.15 /$4.5793 .

Recent News

Reunion Gold Corp. (TSX.V: RGD) (OTCQX: RGDFF)

The QualityStocks Daily Newsletter would like to spotlight Reunion Gold Corp. (TSX.V: RGD) (OTCQX: RGDFF) .

Reunion Gold (TSX.V: RGD) (OTCQX: RGDFF) has announced that, further to its news release of Feb. 13, 2023, it has settled the claim brought by Barrick Gold Corporation (NYSE: GOLD) on a mutually acceptable basis. According to the update, the company and Barrick have agreed that the strategic alliance agreement entered into by them on Feb. 3, 2019, has been terminated. The parties have no outstanding obligations under the agreement, and there are no properties subject to the agreement. A consent dismissal order will be entered in the Ontario Superior Court to dismiss the claim.

To view the full press release, visit

Reunion Gold Corp. (TSX.V: RGD) (OTCQX: RGDFF) is a leading gold explorer in the Guiana Shield, South America. In early 2021, the Company announced an exciting new greenfield gold discovery at its Oko West project in Guyana, where, after 22 months of resource definition drilling, the Company has announced an initial Mineral Resource Estimate (MRE) containing 2.475 Moz of gold in Indicated resources at 1.84 g/t and 1.762 Moz of gold in inferred resources at 2.02 g/t contained within a pit shell outline. Preliminary metallurgy results performed by the company, consisting of 8 bottle roll tests obtained strong results, averaging just under 90% recoveries on average. The Company is continuing with additional development activities at Oko West, including environmental base line studies and additional metallurgical work relating to the delivery of a PEA by year end 2023. In addition, Reunion Gold is currently exploring several priority targets in the Oko West project area on which the company feels there is good potential to add additional resource ounces. This includes the opportunity to grow the initial mineral resource estimate (MRE) released on June 13, 2023, and to discover additional gold ounces at Oko West outside of the resource area.

The Guiana Shield remains one of the most prospective exploration locations globally for the discovery of world class orogenic gold deposits. The shield, including both Guyana and Surinam, contain large relatively underexplored greenstone belts, from which Reunion Gold expects many more significant gold discoveries could emerge in the coming years.

Oko West Project

Reunion Gold’s Oko West Project is a brand-new gold discovery in northwest Guyana located within the historical Oko gold district. Alluvial gold has been mined from the Oko district since the turn of the century, but very little primary gold has been mined or even explored for to the best of the company’s knowledge. The project comprises a prospecting license with an area of approximately 44 square kilometers and is 100% held by Reunion’s Guyanese subsidiary.

In 2020, Reunion Gold’s geochemical survey, trenching and initial 1000 m drill program discovered and confirmed the presence of gold mineralization in this Orogenic gold system. The gold occurs in the eastern edge of the project area, along a 6km long sheared contact between a granitoid intrusion and a meta volcanic-meta sedimentary rock package. The MRE is located within the Kairuni zone, which represents the northern most 1.9 km of the 6 km long contact.

“We are advancing our Oko West project along two tracks. The first is to advance the exploration programs outside of the Kairuni zone, aimed at outlining and discovering additional gold mineralization within our Prospecting License. On this front, I am very excited by the results from the initial Scout RC Geochem drill program that is defining new targets west of our Kairuni zone,” Rick Howes, President and CEO of Reunion Gold, stated in a recent news release. In addition to the targets west of the Kairuni zone, the company has also commenced exploration work on the southern ~ 4 km of the same sheared contact that hosts the Kairuni zone MRE. In addition, the company feels that the MRE marks the size of the Kairuni resource at a point in time and that there is good potential to continue to grow the resource. The MRE remains open at depth below the resource pit outline in the block 4 area and also to depth and along strike in the block 5 and 6 areas. In addition to the exploration programs, the second strategic track is to rapidly advance the Kairuni zone along the path to development. To that end the company is moving forward with the engineering and other studies, including more detailed metallurgical studies, that will support the release a PEA on the Kairuni zone by year end 2023 The company feels that the rapid advancement of development of Kairuni zone MRE, while in parallel continuing to explore for additional ounces on the project, is the best path to try and maximize shareholder value in the shortest period of time.


Guyana boasts a long history of mining gold, bauxite, diamonds and manganese. Still, the greenstone belts of the Guiana Shield remain relatively unexplored when compared to the analogous regions of the West African Shield (Birimian), which, according to geological evidence, was once connected to the Guiana Shield, forming a contiguous craton prior to the Mesozoic period.

Despite a historical lack of accessibility and low exploration intensity, several significant large-scale projects have emerged in the Guiana Shield, including Aurora, Oko West, Oko Main, Toroparu and Omai. Guyana is English speaking with a British based parliamentary and legal system and boasts the world’s fastest growing economy on the back of significant offshore oil discoveries by Exxon and its partners. It is expected that a significant amount of the revenues from oil production will be invested in improving the infrastructure, education and health care and agriculture within the country.

Market Opportunity

The World Gold Council, an industry association representing gold producers with hundreds of mining operations in nearly 50 countries around the world, called 2022 the “strongest year for gold demand in over a decade.” Annual gold demand jumped 18% YoY due to “colossal central bank purchases, aided by vigorous retail investor buying and slower ETF outflows.”

Despite this spike in demand, total annual gold supply increased by just 2% in 2022, halting two years of successive declines but failing to challenge 2018 highs. This supply-demand imbalance could provide a favorable market environment as Reunion Gold continues to advance drilling programs at its 100%-owned Oko West Project.

Management Team

Successful exploration and the discovery of significant deposits in any given region require immense amounts of local knowledge and experience. This is the principle around which Reunion Gold has built its management team. In total, the company’s leadership boasts over 225 years of combined experience in the Guiana Shield.

David Fennell is the Executive Chairman of Reunion Gold, a position he has held since the company’s inception in 2003. He has 40 years of experience in the mining industry. He received a law degree from the University of Alberta in 1979 and practiced law until he founded Golden Star Resources Ltd. in 1983. During his term as President and CEO, Golden Star became one of the largest and most successful exploration companies. While at Golden Star, he was instrumental in the discovery and development of the Omai Gold Mine in Guyana and the Gross Rosebel Mine in Suriname. In 1998, Mr. Fennell became Chairman and CEO of Hope Bay Gold Corporation. He held this position through the merger of Hope Bay and Miramar Mining Corporation and remained as Executive Vice-Chairman and Director for the combined entity until its takeover by Newmont Mining Corporation in 2008. Mr. Fennell is currently a member of the board of directors of G Mining Ventures Corp. and Sabina Gold & Silver Corp.

Rick Howes, P.Eng., is the company’s President and CEO. He is a seasoned mining executive with over 39 years of experience in the mining industry, most recently as CEO of Dundee Precious Metals. Mr. Howes has extensive operating, technical and project development experience in both underground and open pit mines throughout Canada and internationally. In 2009, Mr. Howes joined Dundee Precious Metals, where, as VP and General Manager, he led the transformation of the Chelopech Mine in Bulgaria to reach world-class levels of performance. He became COO in 2011 and oversaw several significant growth capital development projects, including the expansion of the Chelopech Mine, the upgrade and expansion of the Tsumeb Smelter in Namibia and the development of the greenfield Ada Tepe open pit gold mine in Bulgaria. He was appointed CEO in April 2013, leading Dundee’s transformation from a junior gold producer to a multi-asset mid-tier gold producer generating strong free cashflow and solid returns to shareholders. Mr. Howes has been recognized as a visionary leader in mining, organizational innovation and transformation and was recognized as the Outstanding Innovator of 2016 by the International Mining Technology Hall of Fame.

Alain Krushnisky is the CFO of Reunion Gold. He brings to the company years of experience in the mining sector, including 10 years with Cambior Inc. (now IAMGOLD) in capacities such as Vice-President and Controller. Since 2004, Mr. Krushnisky has been doing consulting work for various publicly listed exploration and mining companies. He graduated from the University of Ottawa in 1983 with a bachelor’s degree in commerce and is a Chartered Professional Accountant.

Justin van der Toorn is the company’s VP Exploration. He is an exploration geologist with 18 years’ experience in the minerals industry, leading and managing exploration teams from grassroots activities through to discovery and resource definition drilling. Mr. van der Toorn’s previous experience has been in a range of commodity and deposit styles, including extensive work in Carlin-style gold, low- and high-sulphidation epithermal, porphyry and orogenic gold systems. He holds an MSci degree in Geological Sciences from the Royal School of Mines, Imperial College London. He is registered as a Chartered Geologist (CGeol) of the Geological Society, and a European Geologist (EurGeol) by the European Federation of Geologists.

Doug Flegg is the company’s business Development advisor. Doug has over 35 years’ experience in mining and mining finance with senior positions in research, portfolio management and global equity sales. Previously, Mr. Flegg was Managing Director Global Mining Sales with BMO Capital Markets where he was involved in raising $35 billion in over 200 corporate financings. Since 2016 he has been providing business development, strategic, and financing advice to corporate mining clients. Mr. Flegg also has a B.Sc. in Geology, work experience as a geologist and an MBA from Queens University.

Reunion Gold Corp. (OTCQX: RGDFF), closed Thursday's trading session at $0.3343, up -0.639025%, on 26,200 volume with 00 trades. The average volume for the last 3 months is 147,724 and the stock's 52-week low/high is $0.2123 /$0.46 .

Recent News

Clene Inc. (NASDAQ: CLNN)

The QualityStocks Daily Newsletter would like to spotlight Clene Inc. (NASDAQ: CLNN).

Clene (NASDAQ: CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidiary Clene Nanomedicine Inc., today announced new data from the 12-month long-term open label extension ("OLE") of the CNM-Au8(R) treatment arm in the HEALEY ALS Platform Trial. A key biomarker of neurodegeneration, Neurofilament Light Chain ("NfL") is released from neurons following axonal injury, especially in people living with ALS, where higher levels of NfL have been found to predict more rapid decline in clinical function and increased mortality risk. As detailed in the announcement, CNM-Au8 30mg treatment reduced plasma NfL levels compared to baseline. "As consensus is building that neurofilament is an important biomarker reasonably likely to predict clinical benefit, it is important to see NfL continue to decrease during long-term follow-up, and correlate with time to event clinical outcomes in the Clene regimen of the double-blind and OLE portions of the HEALEY ALS Platform Trial," said James D. Berry MD. Dr Berry is associate professor of neurology, chief of the motor neuron disorder division and director of the Neurological Clinical Research Institute at Massachusetts General Hospital. The company also provided an ALS regulatory update from its recent meeting with the U.S. Food and Drug Administration ("FDA"). Clene met with the FDA to discuss CNM-Au8 for the treatment of ALS, presenting initial clinical and NfL biomarker results from completed phase 2 ALS studies and evidence of long-term survival data from these studies as well as supportive safety data. The FDA determined that the initial findings were insufficient to support accelerated approval at this time. Clene is looking forward to providing supplemental data for further engagement with the FDA in the first half of 2024, including additional long-term clinical evidence and biomarker results of CNM-Au8's treatment benefit in people living with ALS. "As we continue to analyze the data from our phase 2 clinical program, we believe the evidence supports that CNM-Au8 treatment improved survival in people living with ALS," said Benjamin Greenberg, M.D., Clene's head of medical. "We are also encouraged that the recently disclosed long-term NfL biomarker decreases are consistent with delayed clinical time-to-event outcomes." To view the full press releases, visit and

Common knowledge coupled with numerous polls on lifestyle and longevity indicate that exercise generally contributes to longer lives. Physicians consistently encourage their patients to exercise regularly, and many experts contend that the modern sedentary lifestyle has significantly contributed to poor health and reduced lifetimes. However, a recent Finnish Twins Cohort Study report has suggested that exercise may not be as integral to longevity as previously thought. The report notes that "leisure time physical activity" has little direct effect on lifespan, questioning the conventional knowledge that incorporating exercise into your lifestyle can help you live longer. As companies such as Clene Inc. (NASDAQ: CLNN) work to bring to market treatments aimed at reviving mitochondrial health, the quest to boost longevity will have some proven approaches patients can leverage.

Clene Inc. (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).

Its lead drug candidate is CNM-Au8®, an oral suspension developed to restore neuronal health and function by increasing energy production and utilization by driving critical cellular energy producing reactions that enable neuroprotection and remyelination to increase neuronal and glial resilience to disease-relevant stressors. CNM-Au8 is being studied in various clinical trials, including the Harvard/MGH Healey ALS Platform clinical trial for patients with ALS; RESCUE-ALS, a completed proof-of-concept clinical trial in patients with early symptomatic ALS; the REPAIR trials, completed target engagement clinical trials showing brain energy metabolite change with CNM-Au8; and a completed MS clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing MS. The company also has a nanotherapeutic platform of drug discovery.


CNM-Au8, Clene’s lead asset, is a highly concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. Multiple pathogenic insults contribute to neuronal death. Mitochondrial dysfunction and NAD+ decline is a common final pathway in neurodegeneration, with NAD+ as a critical determinant of cell survival and function. CNM-Au8’s catalytic mechanisms target the energetic deficits, oxidative stress and accumulation of misfolded proteins that are common to many neurodegenerative diseases.

The unique catalytic mechanism of action of CNM-Au8 is hypothesized to act as a neuroprotective and remyelinating therapy in neurodegenerative disease states in order to: (1) drive, support and maintain beneficial metabolic and energetic cellular reactions within diseased, stressed and/or damaged cells, (2) directly catalyze the reduction of harmful, reactive oxygen species (“ROS”) and (3) promote protein homeostasis via activation of the heat shock factor-1 pathway, recognized to dampen the cytotoxicity caused by misfolded and denatured proteins, which are known to occur ubiquitously in neurodegenerative diseases.

CNM-Au8 is used in combination with other agents, has no known drug-drug interactions, and is designed to improve function and survival. The clinical effects of both function and survival were seen in its clinical ALS trials, as earlier announced.

More than 500 estimated years of collective exposure across ALS, MS, and Parkinson’s disease participants in CNM-Au8 clinical trials and Expanded Access Protocol (compassionate use) programs have been recorded without any observed safety signals.

CNM-Au8 is a federally registered trademark of Clene Inc. Clene, based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland, began in 2013.

Market Opportunity

ALS is the most prevalent adult-onset progressive motor neuron disease, affecting approximately 30,000 people in the U.S. and an estimated 500,000 people worldwide, with a life expectancy of typically three to five years. Clene estimates that global ALS treatment sales will be greater than $1 billion annually within the coming few years. Additional treatments affecting daily function and survival remain the market need.

Additionally, there are more than 2 million MS patients globally, and Clene estimates the market size to be worth more than $23 billion annually. While the MS community has been successful at limiting relapses, non-relapsing MS patients continue to clinically deteriorate even while receiving effective immunomodulatory disease-modifying therapies (“DMTs”). A critical unmet medical need remains for therapeutic interventions that protect neuronal function and myelin health independent of immunomodulation to address progression independent of relapse activity.

Management Team

Robert Etherington is President, Director and CEO of Clene. He has more than 30 years of sales, marketing and leadership experience in the pharmaceutical industry. Prior to joining Clene, he worked at Actelion Pharmaceuticals, the largest biopharma company in the European Union prior to its acquisition by Johnson & Johnson in 2017, where he led that company’s U.S. commercial operations. He began his pharmaceutical sales and marketing career at Parke-Davis, a division of Pfizer, where he rose to the position of Team Leader overseeing the drug Lipitor.

Mark Mortenson is Chief Science Officer at Clene. He is co-inventor of the technology platform developed to produce the company’s therapeutics. He is the inventor or co-inventor on 32 other U.S. patents and hundreds of corresponding international patents. He is a former chief patent counsel responsible for 5,500 U.S. and international patents and patent applications. He holds bachelor’s degrees in physics and ceramic engineering from Alfred University, a master’s degree in materials science from Penn State University and a J.D. from George Washington University.

Benjamin Greenberg, M.D., MHS, FAAN, is Head of Medical at Clene. He is an internationally recognized expert in disorders of the central nervous system. He is currently professor of neurology and Vice Chair of Clinical and Translational Research in the department of Neurology at University of Texas Southwestern Medical Center in Dallas. He holds a bachelor’s degree from Johns Hopkins, a master’s degree in molecular microbiology and immunology from the Johns Hopkins School of Public Health and graduated from Baylor College of Medicine. He served residency in neurology at The Johns Hopkins Hospital.

Morgan R. Brown is CFO at Clene. He has more than 30 years of finance and accounting experience, with 23 years at biotech, pharmaceutical and medical device companies. He has served in similar roles at Lipocine Inc., Innovus Pharmaceuticals, World Heart Corp., Lifetree Clinical Research and NPS Pharmaceuticals Inc. He previously worked at accounting firm KPMG. He is a CPA with a bachelor’s degree in accounting from Utah State University and an M.S. in business administration from the University of Utah.

Clene Inc. (NASDAQ: CLNN), closed Thursday's trading session at $0.315, up -38.835%, on 8,895,831 volume with 00 trades. The average volume for the last 3 months is 563,595 and the stock's 52-week low/high is $0.2759 /$1.99 .

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.